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Abstract of thesis entitled: 
Generation of induced pluripotent stem cells from mouse cancer cells 
-Novel approach to cancer therapy 
Cancer arises as a result of mutations and epigenetic changes in oncogenes and 
tumor suppressor genes. However, cancer cells are generally poor stimulators of naive T 
cells. Dendritic cells，which are the most potent antigen-presenting cells of immune 
system, have therefore been used in experimental and clinical settings to present tumor 
antigens for activating anti-tumor T cell responses. The mutated genes in cancer cells 
lead to expression of neoantigens, forming a molecular "fingerprint" which uniquely 
characterizes the tumor. Initial studies in mice together with an accumulating body of 
clinical experience, indicate that the immune system can recognize and reject tumors, 
despite the low efficiency. 
In 2006, a major breakthrough was reported by Takahashi and Yamanaka 
describing the generation of embryonic stem cells-like phenotype cells, named induced 
pluripotent stem cells (iPSCs), from reprogramming of embryonic and adult fibroblasts 
using four transcription factors, known as the Yamanaka factors. Since then, a number of 
adult somatic cell types, including cancer cells, have been found amenable to iPSC 
reprogramming. These induced pluripotent stem cells are able to generate different types 
of cells including dendritic cells. 
Here, we set out to study a novel approach to induce anti-tumor immune response 
by transforming tumor cells into dendritic cells through stem cell reprogramming. 
In this study, I reprogrammed mouse Lewis lung carcinoma cells, D122, into 
induced pluripotent stem cells using plasmid vector carrying the Yamanaka factors. The 
reprogrammed cells expressed a host of chacteristic stem cells markers, including Nanog, 
Oct4, and SSEA-1, and similar gene expression profile as the mouse embryonic stem 
cells. Furthermore, these cells showed certain differentiation potential including forming 
embryoid bodies, and by their ability to undergo retinoic acid (RA) induced 
ii 
differentiation into neural-like cells which were positive in Pax6 and Nestin expression. 
Pax6 and Nestin are markers for neural progenitors. 
My work is a piece of evidence to show cancer cells D122 can be reprogrammed 
to iPSC-like cells and carry certain differentiation potential. Further work will be done on 
differentiating those cells into dendritic cells and assessing their capability of inducing 
anti-tumor response in mouse tumor models. 
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Co-authors: Frances K.Y.Lin, Y.L Chui 
Abstract: 
Since the advent of induced pluripotent stem cells (iPSC) using Yamanaka factors, 
many different somatic cell types have been shown amenable to reprogramming into 
pluripotent stem cells. iPSCs express stem cell phenotype, shown stem cell like 
epigenetic pattern of Nanog and Oct4 genes, and are able to differentiate into 3 germ 
layers that give rise into viable embryos. However, only a few groups have reported on 
reprogramming cancer cells. 
There is accumulating evidence that cancer is tightly linked with stem cells. Many 
pluripotent genes are overexpressed in cancer cells. This implies that cancer may arise 
from mutated stem cells. Alternatively, somatic cells may somehow gain some degree of 
pluripotency, which enables them to undergo self-renewal, differentiation, metastasis and 
become resistant to chemotherapy and radiation. Interestingly, most of the genes involved 
in making iPS cells (Myc, Nanog, Klf4, Sox2, Lin28, Oct4 and loss of p53 function) are 
linked to cancer. 
To date, there is little work on exploring the use of iPSC to study the cancer stem 
cell. Our group has been working on reprogramming a metastatic mouse Lewis lung 
carcinoma line, D122, using plasmid and retrovirus carrying Yamanaka factors. The 
established iPSC-like cells show Nanog, Oct4, and SSEA-1 expression, and high 
upregulation of a host of other pluripotency genes like Rexl , Utf l and DppaS. 
This is a piece of evidence to show that cancer cells can be reprogrammed to 
iPSC-like cells, which may serve as a model system for studying cancer stem cells, 
differentiation potential and oncogenesis. 
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CHAPTER I INTRODUCTION 
1.1 Pluripotent stem cells 
1.1.1 Characteristics of pluripotent stem cells 
Stem cells are defined by two properties: long-term self-renewal and 
pluripotency (Gardner and Beddington, 1988). Self-renewal is the division of a 
cell to give rise to two daughter cells, at least one of which is identical to the cell 
from which they arose. Differentiation occurs when the stem cell becomes a 
more specialized cell type and loses the capacity for self-renewal (Smith, 2001). 
Pluripotency can be defined in functional and molecular terms. 
Functionally, pluripotency refers to the ability of a cell to give rise to cell types 
of three germ layers of embryo, including ectoderm, mesoderm and endoderm, as 
well as germline, but not all extraembryonic tissues. In molecular level, 
pluripotency described as expression of molecular regulators that is essential for 
their establishment and maintenance (Ralston and Rossant, 2010). 
1.1.2 Origin of pluripotent stem cells 
During early cleavage of the embryo, the zygote and blastomeres exhibit 
the characteristic of totipotency. As the development proceeds, the 
developmental potency of the cells are restricted and become specialized 
progenitor cells or terminally differentiated cells. Pluripotent cells can be derived 
from the germ cell lineage, from post-implantation embryos (Brons, et al., 2007, 
Tesar, et al, 2007) and by reprogramming of somatic cells (Takahashi and 
Yamanaka, 2006). 
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1.1.2.1 Embryonic carcinoma cells (EC) 
The embryonic carcinoma (EC) cells are derived from teratocarcinomas, 
a germ cell tumor. The EC cells have the ability to self-renewal indefinitely and 
can differentiate into multiple lineages (Kleinsmith and Pierce, 1964), despite 
karyotypic abnormalities are frequently observed (Brinster, 1974). 
1.1.2.2 Embryonic stem cells (ESC) 
Embryonic stem cells (ESC) are first isolated from normal embryos from 
the inner cell mass of blastocysts at dpc 3.5 (Evans and Kaufman, 1981; Martin, 
1981). Mouse ESCs recapitulate full developmental potential when injected into 
mouse blastocysts, contributing cells to the three germ layers and to the germline 
of chimeric animals. 
1.1.2.3 Epiblast stem cells (EpiSC) 
Epiblast stem cells (EpiSC) are derived from the epiblast of the implanted 
embryo. Epiblast is a single layer of epithelial cells and originates from the inner 
cell mass after implantation of the embryo. EpiSCs are established by explanting 
the epiblast from embryonic day 5.5-7.5 of post-implantation mouse embryos in 
growth medium supplemented with Fgf2 (basic fibroblast growth factor) and 
Activin (Brons, et cd., 2007; Tesar, et al., 2007). Although they are described as 
pluripotent, they are more limited developmental potential than ESCs and highly 
inefficient in generating chimeras. 
2 
1.1.2.4 Embryonic germ cells (EG cells) and adult germline stem cells: 
Embryonic germ cells (EG) are derived from primordial germ cells from 
embryonic day 8.5 embryos in vitro (Matsui, et al., 1992). Mouse EG cells are 
morphologically very similar to mouse embryonic stem cells (mESC) and 
express typical ES cell surface markers. Also they can contribute to tissues in 
chimeric mice including germ cells (Labosky, et al., 1994). In contrast to ES 
cells, EG cells still have some characteristics of the original primordial germ 
cells (PGCs) such as genome wide demethylation and absence of genomic 
imprinting (Labosky, et al., 1994; Tada, et al., 1997). Differentiation into several 
lineages was shown in early passage EG cells, but has to be confirmed in stable 
lines and the formation of teratomas. 
Adult germline stem cells like spermatogonial stem cells derived from 
newborn and adult male gonads also generate ES-like cells. These cells are able 
to induce teratoma formation and contribute to chimeras, although very low 
efficiency (Kanatsu-Shinohara, et al, 2004; Guan, et al., 2006). 
1.1.2.5 Induced pluripotent stem cells (iPSC) 
Induced pluripotent stem cells are ES-like cells first generated from 
mouse embryonic fibroblast with induction of four transcription factors, Oct3/4, 
Sox2, Klf4 and c-Myc, which are referred to as Yamanaka factors (Takahashi and 
Yamanaka, 2006). Features and generation of induced pluripotent stem cells 
generation will be discussed in the later context. 
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1.1.3 Pluripotency in Embryonic Stem Cells 
Embryonic stem cells are able to differentiate into three germ layers, and 
the proper development of the ES cells rely on a precise series of events 
controlled by tight regulation of specific genes. Conversely, accurate gene 
expression is dependent on transcriptional activity which is responsible for 
regulation of biological processes. 
The exact mechanism responsible for ESC self-renewal and pluripotency is 
still largely unknown (Loh, et al., 2006). 
Pluripotency of ESC under cell culture conditions is maintained through 
extrinsic and intrinsic factors. Pluripotency of ESC in culture requires extrinsic 
cytokine LIF (Smith, et al, 1988; Williams, et al., 1988) and Bone 
morphogenetic protein (BMP) under serum-free conditions (Ying, et al., 2003a). 
Several transcription factors Oct-3/4, Sox2 and Nanog, were identified and 
characterized to be responsible for intrinsic pluripotency. 
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1.1.3.1 Extrinsic pluripotency signals 
1.1.3.1.1 LIF signaling 
In the presence of fetal calf serum in conventional culture, leukemia 
inhibitory factor (LIF) is regularly added to the culture condition to maintain 
pluripotency. LIF is a member of the LI6 family of cytokines that signals through 
a transmembrane glycoprotein-130 (gpl30) (Boulton, et al, 1994). 
LIF maintains the pluripotency through binding to the LIF receptor 
(LIFR), thereby mediating the heterodimerization of the LIFR with gplSO. This 
LIF signaling cascade subsequently activates the signal transducer and activator 
of transcription-3 (Stat3) via phosphorylation through Janus tyrosine kinase 
(JAK) to inhibit differentiation (Burdon, et al., 2002). 
The overexpression of Stat3 is sufficient and necessary to maintain 
pluripotency of ESC in the absence of LIF (Matsuda, et al, 1999) whereas the 
inhibition of Stat3 induces differentiation (Niwa, et al” 1998). Surprisingly, 
mouse embryos lacking Stat3 are able to develop into a phase beyond ES cell 
derivation in vivo indicating that different pathways may be involved in 
sustaining pluripotency (Takeda, et al., 1997). 
A second possibility known to circumvent LIF dependence of mouse ESC 
is the overexpression of Nanog (Mitsui, et al., 2003), but a connection between 
the overexpression of Stat3 and Nanog was not drawn until very recently, Niwa 
and colleagues described that LIF is actually regulating two different signaling 
pathways both responsible for the maintenance of pluripotency. On one hand, 
LIF is activating Klf4 via the Jak-Stat pathway, which in consequence leads to 
the expression of Sox2 but not Nanog. On the other hand, LIF interacts with the 
PI3 kinase-Akt signaling cascade thereby activating Tbx3. TbxS subsequently 
induces the expression of Nanog, which in concert with Sox2 regulates Oct3/4 
(Niwa, et al., 2009). This triad of key transcription factors regulates itself and 
other genes associated with sternness (Boyer, et al” 2005, Loh, et al., 2006) 
5 
1.1.3.1.2 BMP signaling 
Without addition of serum, addition of LIF alone is not sufficient to 
maintain pluripotency and the ESC undergo neural differentiation. Therefore, 
Ying proposed that inhibition of neural differentiation might support serum-free 
self-renewal. With the supplementation with Bone Morphogenetic Proteins 
(BMP), ES cells under serum-free condition can be propagated in a pluripotent 
state as BMP is able to suppress the neuronal differentiation through SMAD 
mediated expression of inhibitor of differentiation (Id) genes (Ying, et al., 
2003a). 
In ESC cultivated in N2B27 medium without LIF and BMP, the 
overexpression of Nanog enables the cells to express Idl and Id3 indicating that 
Nanog influences the expression levels of Id genes (Ying, et al., 2003a). Another 
proposed role for BMP is the inhibition of p38, which would otherwise inhibit 
the expression of genes sustaining with pluripotency (Qi, et al, 2004). The 
paradigm of dependence of mouse ESC on extrinsic sternness signals such as the 
above mentioned LIF and BMP were challenged though (Ying, et al., 2008). 
1.1.3.1.3 Other signaling pathways 
By the use of small molecules inhibiting differentiation initiated by 
Mitogen-activated protein kinase (MAPK) and Glycogen synthase kinase 3 
(GSK-3) signaling, it is possible to maintain pluripotency in mouse ESC in the 
absence of LIF and BMP (Silva, et al., 2008). 
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1.1.3.2 Intrinsic sternness factors 
1.1.3.2.1 Oct4 Expression in Embryonic Stem cells 
Octamer 4 {Oct-4) is a homeodomain transcription factor of the POU 
family essential for expression and maintenance of pluripotency in ESC (Ovitt 
and Scholer, 1998, Pesce, et al, 1998). 
It was the first gene identified as a master regulator of pluripotency 
(Nichols, et al., 1998). It was demonstrated that (9cr4-deficient embryos develop 
to blastocyst stage but the inner cell mass cells are not pluripotent. In humans 
and mice, Oct4 expression is limited to ESC, unfertilized oocytes and primordial 
germ cells (Pesce, et al., 1998, Nichols, et al, 1998, Palmieri, et al., 1994, 
Rosner, et aL, Scholer, et al., 1990, Yeom, et al., 1996). The expression profile 
of Oct4 suggests that it may regulate cell fate during early developmental control 
(Scholer, et al., 1990, Scholer, et al., 1989). 
The cell fate ofESCs is tightly regulated by the expression of Oct4. 
Overexpression of Oct4 in mouse ESCs causes differentiation towards 
endodermal and mesodermal lineages, whereas repression results in trophoblast 
formation (Niwa, et al” 2000). Therefore, the expression of Oct4 in mouse ESC 
must be maintained within a specific range to sustain stem cell self-renewal (Pan, 
etaL, 2002). 
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1.1.3.2.2 Sox-2 Expression in Embryonic Stem Cells 
Sox2 is a member of Sex Determining Region-Y (SRY)-High Mobility 
Group (HMG) box gene family. It is expressed in ES cells, early embryos, germ 
cells and neural stem cells. It often partners with Oct4 to regulate gene 
expression (Rodda, et al., 2005, Ambrosetti, et al, 1997). Unlike Oct4, Sox2 is 
not only expressed in ESC, unfertilized oocytes and primordial germ cells, but 
also present in multipotent cells of the extraembryonic ectoderm (Avilion, et al” 
2003). 
In Sox2 knockout mice model, it has been demonstrated that Sox2 is 
required for epiblast and extraembryonic ectoderm suggested that Sox2 and Oct4 
cooperatively specify the fate of pluripotent stem cells at implantation (Avilion, 
et al., 2003). The Sox2 deficient ESCs improperly differentiated into 
trophectoderm-like cells (Masui, et al., 2007). However, ectopic expression of 
Oct4 could rescue the pluripotent phenotype in Sox2 deficient ESCs. This 
indicates the main function of Sox2 is to stabilize ES cells in a pluripotent state 
by maintaining the Oct4 expression level. Thus Sox2 stabilizes ES cells in a 
pluripotent state by maintaining the requisite level of Oct4 expression (Li, et al., 
2007, Masui, et al.，2007). 
Overexpression of Sox2, beyond its critical range, will leads to the 
differentiation of ES cells (Fong, et al., 2008). Therefore, Sox2 also plays an 
important role in ES cell self-renewal and pluripotency. 
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1.1.3.2.3 Nanog Expression in Embryonic Stem Cells 
Nanog is an NK-2 class homeobox-containing transcription factor that 
plays an essential role in regulating early embryonic development and 
maintaining pluripotency in the cells of the ICM (Chambers, et al., 2003). It is 
specifically expressed in pluripotent cells and the inner cell mass of the 
blastocysts embryo (Chambers, et aL, 2003; Mitsui, et al., 2003). 
Nanog, also known as Ecat4, was named after Tir Nan Og (the land of 
the young) as it has the ability to sustain stem cells self-renewal over a month 
(Chambers, et al., 2003; Mitsui, et al” 2003) in the absence of LIF which is 
independent of LIF/STAT3 (Chambers, et al., 2003). 
ES cells lacking Nanog can be derived, but they tend to differentiate into 
extraembryonic endoderm lineages even in the presence of LIF (Mitsui, et al, 
2003). Another group reported that even heterozygous Nanog mutant ES cells 
were unstable and susceptible to spontaneous differentiation (Hatano, et al, 
2005). 
Homeoprotein Nanog has two most fundamental characteristics, one is 
the role in pluripotentcy of both inner cell mass (ICM) and embryonic stem (ES) 
cells, and another is the ability to maintain ES cell self-renewal that is 
independent of LIF/Stat3. Nanog gene expression persists in all embryonic and 
extra-embryonic tissues except at the spherical stage. 
Nanog has two potent transactivators (Pan, et al., 2006; Pan and Pei, 
2005), suggesting that Nanog could be an activator of Oct4 expression. Indeed, 
Nanog behaves as a strong activator of the Oct4 promoter, thus participating in 
the regulation of Oct4 expression in ES cells (Pan, et al., 2006). 
Like Oct4, Nanog expression decreases rapidly as ESCs differentiate. 
Decreased expression of Nanog predisposes the differentiation to extra-
embryonic lineages, but Nanog is not absolutely required for ES cell 
pluripotency (Chambers, et al, 2003). 
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11.3.2.4 Transcriptional Regulation of Oct4, Nanog and Sox2 in Embryonic 
Stem Cells 
Oct4, Nanog and Sox2 are key components responsible for the pluripotency 
in ESCs, yet, none of these factors can maintain ESC identity alone. 
Studies have shown that Oct4 and Sox2 form complex whereas the Nanog 
proximal promoter also contains an Oct-Sox responsive element that must bound 
by Oct4 and Sox2 for Nanog transcription (Kuroda, et ai, 2005, Rodda, et al., 
2005). Oct4, Nanog and Sox2 form an autoregulatory pluripotent circuitry that 
binds the promoters of several hundred-target genes (Boyer, et al., 2005). They 
work as transcriptional activators of genes that maintain pluripotency including 
themselves as well as transcriptional repressors of genes promoting 
differentiation (Smith, et al, 1988; Williams, et al” 1988; Wang, et al, 2006; 
Ivanova, et al., 2006). 
Also, the expression levels of these three genes are tightly regulated, 
obstruction of the normal relative levels of one of these factors could alter the 
expression of the others, resulting in improper gene expressions. For example, a 
normal ICM and epiblast fail to form in the absence of Oct4 and Nanog 
expressions. As a result, the cells from which Oct4 was deleted no longer express 
Nanog, and the cells from which Nanog was deleted no longer express Oct4 
(Chambers, et al., 2003). Similarly, when Sox2 was removed from ESC, Oct4 
expression was downregulated (Masui, et al., 2007) and Nanog transcription was 
severely compromised (Rodda, et al., 2005). 
Furthermore, genome-wide chromatin immunoprecipitation analysis 
demonstrated that Oct4, Sox2 and Nanog share many target genes in both the 
mouse and the human ES cells (Boyer, et al., 2005; Loh, et al, 2006). 
Together, Oct4 and Sox2 are key regulators of pluripotency that interact in 
negative feedback regulatory circuits and Nanog mainly functions as an 
important modulator of pluripotency (Boyer, et al., 2005; Wang, et al., 2006; 
Ivanova, et al., 2006). 
10 
1.1.3.2.5 Other Pluripotent genes expressed in ES cells 
From digital differential display experiment, the expression sequence tag 
libraries from mouse ES cells and those from various tissues were compared 
(Mitsui, et al., 2003). A number of genes overrepresented in ES cell-derived 
libraries were identified. Among twenty genes with highest enrichment were 
Oct4, Utfl (Okuda, et al, 1998) and Rexl (Rogers, et al., 1991), which had been 
experimentally identified as ES cell specific markers. 
1.1.3.2.5.1 Utfl 
Undifferentiated embryonic cell transcription factor 1 (Utfl) is a 
transcription factor first identified as a transcriptional co-factor that is expressed 
in mouse ES cells in a stem-cell-specific manner (Okuda, et al., 1998). It 
possesses a stem-cell-specific enhancer that is activated by Oct4 (Nishimoto, et 
al., 1999) and contributed to the proliferation of ES cells, possibly by promoting 
cell cycle progression. Downregulation of Utfl resulted in decreased 
proliferation of ES cells, as well as decreased teratoma formation in vivo 
(Nishimoto, et al., 2005). Expression of Utfl specifically observed in early 
mouse embryos, inner cell mass (ICM), and primitive ectoderm from ICM, not 
mesoderm, embryonic ectodermal cells identified at the early primitive streak 
stage (Okuda, et al, 1998). 
1.1.3.2.5.2 Rexl 
Reduced expression gene 1 {Rexl), also known as Zfp42, encodes C2H2 
zinc-finger protein and is highly expressed in undifferentiated mouse ES cells, 
and used as ES specific markers (Rogers, et al., 1991). It has been reported that 
RNAi knockdown ofZfp42 in mouse ES cells induced ES cells differentiation to 
endoderm and mesoderm lineages (Zhang, et al., 2006a). However, recent results 
show that in the absence of Rexl mouse ES cells remain pluripotent and 
contribute whole embryos after blastocyst injection (Masui, et al., 2008). 
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1.1.3.2.5.3 Esrrb 
Estrogen-related-receptor P {Esrrb) belongs to the family of orphan 
nuclear receptors. It is known to positively regulate Oct4 and Nanog expression, 
and its overexpression alone was able to maintain self-renewal and pluripotency 
of mouse ES cells (Zhang, et al., 2008). The Esrrb knockout embryos die around 
E10.5 due to the impaired placental formation and abnormal chorion 
development (Luo, et al., 1997). 
Esrrb is also been shown able to substitute Klf4 to reprogram mouse 
embryonic fibroblast successfully, albeit in lower efficiency (Feng, et al., 2009). 
1.1.3.2.5.4 Eras 
ESC-expressed Ras (Ems) is the modulators of phosphoinositol-3-kinase 
(PIP3K/Akt) signaling pathway that plays an important role in proliferation and 
maintenance of pluripotency of ES cells. Eras encodes a constitutively active 
form of a Ras-family small GTPase that activates PI3K to stimulate ES cells 
proliferation and is upregulated in ESC and iPSC. Eras expressed specifically in 
mESC and its deletion led to decreased proliferation (Takahashi, et al., 2003). 
1.1.3.2.5.5 Tell 
T-cell leukemia 1 {Tell) is another modulator of phosphoinositol-3-
kinase (PIP3K/Akt) signaling pathway and upregulated in ES and iPS cells. Akt 
was identified in RNAi screen as a regulator of mESC pluripotency (Pritsker, et 
al., 2006). Tel increases the Akt activation by formation a heterodimeric complex 
with Akt. Knockdown of Tell in mouse ES cells impairs self-renewal by 
inducing differentiation and/or repressing their proliferation. However, similar to 
Eras, the direct mechanism is not yet identified. 
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1.1.3.2.5.6 Dnmt31 
DNA (cytosine-5)-methyltransferase 3-like {DnmtSl) is responsible for 
CpG dinucleotide methylation as DnmtSa and DnmtSb. DnmtSl has been shown 
to stimulate the activity of Dnmt3a and DnmtSb (Hata, et al., 2002). 
The establishment of specific DNA methylation patterns is essential for 
the development of the early embryo. DNA methylatransferase DnmtSa and 
DnmtSb are important for de novo methylation and for mouse development 
(Okano, et al., 1999). 
1.1.3.2.5.7 Dppa3 
Developmental pluripotency associated 3 {Dppa3% known as Stella, 
encodes a protein with a SAP-like domain and a splicing factor motif-like 
structure (Payer, et al., 2003). It functions as an important maternal factor and is 
required for the cleavage stages during early mouse embryogenesis; DppaS 




Developmental pluripotency associated 4 {Dppa4) is first appeared as an 
ES cells specific transcript in a comprehensive microarray profiling (Ramalho-
Santos, et al., 2002). And then, it is identified in an electronic screen designed to 
identify transcripts with and Oct4 like expression pattern (Bortvin, et al., 2003). 
It was found clustered closest with Oct4 in a comparison of expression patterns 
of transcripts from various cell type by microarray analysis (Silva, et al, 2008). 
Mouse Dppa4 reemerged in and RNA interference-based functional genomics 
screen for genes potentially controlling self-renewal in ES cells (Ivanova, et al” 
2006). Also, Dppa4 gene locus has been traced as a prominent binding site for 
the core pluripotency factors Oct4, Sox2 and Nanog in "global genome location" 
studies (Babaie, et al., 2007; Boyer, et aL, 2005; Chakravarthy, et al., 2008) 
which suggested an important role in the transcriptional circuitry controlling ES 
cell identity. Dppa4 expressess exclusively in pluripotent cells, preimplantation 
embryo, ES/embryonic carcinoma cells and developing germ line (Maldonado-
Saldivia, et a!., 2007). 
1.1.3.2.5.9 DppaS 
Developmental pluripotency associated 5 (DppaS), also as ESGl 
(Embryonal stem-cell-specific gene 1), is expressed in embryonic germ, 
primordial germ and embryonic stem cells (Astigiano, et al., 1991; Bierbaum, et 
al., 1994; Tanaka, et al., 2002; Bortvin, et al., 2003). It plays an important role in 
pluripotency maintenance in ES cells and necessary for proper embryogenesis. 
Dppa5 is an ES cell-restricted transcript that is exclusively associated with 
pluripotency (Kim, et al, 2005). 
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1.1.3.2.5.10 KIf2 
Klf2 belong to Kruppel-like family of transcription factors. It has been 
shown that a triple knockdown of Klf2 and Klf5 along with Klf4, resulted in 
differentiation of mouse ES cells, suggesting an important function of these 
genes for the maintenance of self-renewal (Jiang, et al., 2008). 
Klf2 has also been shown able to substitute Klf4 to reprogram mouse 
embryonic fibroblast successfully (Nakagawa, et al., 2008). 
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1.2 Somatic cell reprogramming 
1.2.1 Definition of reprogramming 
Reprogramming is the process that converts differentiated cells back to 
pluripotent ones, effectively the reversal of differentiation (Jaenisch and Young, 
2008; Egli, et al.’ 2008). Experimentally, reprogramming has been achieved 
through somatic cell nuclear transfer or through fusion with ES cells. More 
recently, iPS cells technology has accomplished the same feat via the 
introduction of pluripotency transcription factors into somatic cells. 
1.2.2 The history of reprogramming 
It was believed that cell differentiation is an irreversible process; the 
terminally differentiated cells lose the potential of producing other cells. 
However, in several classical studies, differentiated cells are "plastic", and the 
fate of cells can change in response to the extracellular environment. Different 
ways to reverse the status of differentiated cells to pluripotent state are described 
below. 
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1.2.2.1 Reprogramming by nuclear transfer 
In 1952, the seminal somatic cells nuclear transfer studies by Briggs and 
King showed that blastula cell nuclei retain the genetic information required for 
pluripotency when injected into enucleated frog oocytes (Briggs and King, 1952). 
This phenomenon was investigated further by Gurdon and Uehlinger who 
demonstrated that even more differentiated intestinal cells were capable of 
directing development into adult frogs following somatic cell nuclear transfer, 
albeit at low efficiency (app.1%) (Gurdon and Uehlinger, 1966). These early 
cloning experiments proved that nuclei from terminally differentiated cells are 
capable of generating viable cloned animals, and formed the basis of later 
mammalian cloning experiments. 
The creation of the first cloned sheep, 'Dolly' by Wilmut and colleagues 
together with many other later successful mammalian cloning attempts 
convincingly demonstrated that the developmental restrictions established during 
differentiation are due to reversible changes in the epigenome, rather than to 
permanent modification to the genome (Wilmut, et al., 1997). 
These nuclear transfer experiments have shown that all of the genes 
required to create an entire organism are definitively present in the nucleus of the 
specialized cell and can be activated on exposure to reprogramming factors 
present in the oocytes. In other words, cell specialization involved a change in 
gene expression, not in gene content, and the process of differentiation can be 
fully reversed. 
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1.2.2.2 Reprogramming by fusion with ES or EC cells 
In 1976, Miller and Ruddle demonstrated that thymocytes acquired 
pluripotency upon fusion with embryonal carcinoma cells (ECCs) (Miller and 
Ruddle, 1976). Similar results were obtained later by electrofusion with 
embryonic germ cells (EGCs) (Tada, et al., 1997) and mouse ESC (Tada, et al., 
2001). Transplantation of these cells into nude mice results in the formation of 
teratoma consisting various tissues including all three germ layers, confirming 
the pluripotency of these cells. These results suggest that the cytoplasm of the 
oocytes and pluripotent stem cells may contain the factors that induce the 
pluripotency in somatic cells. 
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1.2.2.3 Reprogramming with defined factors 
In order to identify the pluripotency-inducing factors, Yamanaka and 
Takahashi suggested that these pluripotency-inducing factors also play important 
role in the maintenance of pluripotency in ES cells. Therefore, they selected 
three groups of genes which play important roles in the maintenance of ES cells 
identity and potentially inducing pluripotency in somatic cells. 
The first group is responsible for the maintenance of ES cell identity in 
both early embryos and ES cells, including Nanog, Oct4, Sox2, Utfl, Sal4, Sox 15 
and Rexl. Second group consists of growth and tumor related gene products that 
have been shown to play important roles in ESCs, including c-Myc, StatS, B-
catenin, Grb2, Klf4, Tell and Eras. The third group consists of factors that 
specifically expressed in ESCs, but with less defined functions genes, including 
Ecatl, Esgl, Fbxl5, DnmtSl EcatS, Gdfi, Ecatl5-1, Ecatl5-2, Fthll7md Stella 
(Dppa3) (Takahashi and Yamanaka, 2006). 
With the use ofFbxlS "^®��, Pge�mouse embryonic fibroblast (MEF), a 
selection marker driven by jhxl5 a gene known to specifically expressed in ES 
cells. Four transcription factors were identified, Oct4, Sox2, Klf4 and c-Myc 
(known as Yamanaka factor). The MEF after induction of four factors exhibit 
ES-cell-like phenotype, including proliferation, gene expression profile, Nanog 
and Oct4 methylation status. Teratoma including three germ layers was formed 
after injecting to nude mice confirming the pluripotency (Takahashi and 
Yamanaka, 2006). 
Later, the four transcription factors cocktail successfully reprogrammed 
human fibroblast to induced pluripotent stem cells. 
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1.3 Induced pluripotent stem cells 
1.3.1 Transcription factor used for reprogramming to iPS cells 
Transcription factors Oct4, Sox2, Klf4 and c-Myc were used to generate iPS 
cells. These transcription factors have a role in pluripotency (Takahashi and 
Yamanaka, 2006). The mechanisms by which these transcription factors 
influence reprogramming to an undifferentiated state remain to be investigated, 
but little is known already. 
The importance of Oct4 and Sox2 in maintaining pluripotency has been 
discussed in the context above, therefore, the function of Klf4 and c-Myc will be 
discussed in detail. 
1.3.1.1 Klf4 
Kruppel-like transcription factor (Klf4) abundantly presents in ES cells, 
its knockdown does not affect ES cell self-renewal and pluripotency since other 
Klfs compensate for its binding to target sites. However, simultaneous 
downregulation of multiple KLF family members results in ES cell 
differentiation (Jiang, et al., 2008). Klf4, together with other KLFs, binds the 
Nanog enhancer and also shares many DNA targets with Nanog (Jiang, et al., 
2008). Klf4 may also function as a co-factor of Oct4 and Sox2 (Nakatake, et cd., 
2006). 
These suggest the critical role of KLF proteins in the transcriptional 
regulation of pluripotency. Klf4 was also reported to play a role in the 
inactivation of the tumor suppressor p53 resulting in immortalization and might 
therefore also have oncogenic effects (Rowland and Peeper, 2006). 
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1.3.1.2 c-Myc 
c-Myc belongs to a proto-oncogenic Myc family that has been shown to 
be involved in many cancers when its expression is deregulated (Knoepfler, 
2008). The exact role oic-Myc in pluripotency and reprogramming is less clear. 
Pluripotent stem cells have open chromatin structures (Meshorer, et al., 
2006). c-Myc has also been shown to play a role in the widespread maintenance 
of active chromatin (Knoepfler, et al., 2006). Consistently, iPS cells show 
acetylated histone in the promoter regions of several ESC-specific genes 
(Takahashi and Yamanaka, 2006). 
Moreover, decreased c-Myc activity in ES cells led to differentiation 
whereas an increased level of c-Myc might result in apoptosis (Cartwright, et al, 
2005). Therefore, induction of c-Myc during reprogramming might open the 
chromatin and provide binding sites for ES specific transcription factors to 
activate genes important for self-renewal and pluripotency. 
21 
1.3.2 Cornerstone of iPSC generation 
During the development of iPSC generation, several important 
cornerstones were laid. 
After the successful generation of ES-like cells from mouse embryonic 
fibroblasts (MEF) in 2006 by introduction of Oct4, Sox2, Klf4 and c-Myc using 
retroviral induction (Takahashi and Yamanaka, 2006). Similar iPSC was 
established from human cells using the same set of factors (Takahashi, et al., 
2007; Park, et al, 2008). 
In mouse, it has been shown the ability to transmit to the germ line (Okita, 
et al.，2007). The mouse generated with c-Myc, which is a proto-oncogene, are 
prone to tumor development. Therefore, generation iPSC without the use of c-
Myc was established to reduce the risk of tumorgenicity (Nakagawa, et al., 2008; 
Wemig, et al., 2008). Later, mouse iPSCs were shown able to give rise to viable 
mice by tetraploid complementation assays, which is the most stringent test for 
pluripotency (Boland, et al, 2009; Kang, et cd； 2009; Zhao, et al., 2009). 
In humans, iPSC was established from various patient cells (Dimos, et al., 
2008; Ebert, et al., 2009; Park, et al., 2008). Correction of genetic disease was 
also reported (Raya, et al., 2009). 
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1.3.3 Major events in the reprogramming process 
The occurrence of reprogramming process is still largely unknown. The 
exact time scale is hard to state since the process is gradual and only a small 
portion of cells undergo reprogramming. In the case of mouse embryonic 
fibroblast, it takes 1-2 weeks to generate iPSC after induction of reprogramming 
transcription factors. 
As the first report of induced pluripotent stem cells was performed on 
mouse embryonic fibroblast (Takahashi and Yamanaka, 2006), the kinetics study 
of reprogramming was mainly conducted on fibroblast (Brambrink, et al., 2008; 
Stadtfeld, et al., 2008). Despite being a gradual process, it was found that 
successful reprogramming requires stepwise transition through key intermediate 
steps. 
In the early stage, the c-Myc in the reprogramming cocktail induces the 
cellular proliferation of fibroblast, which is believed to play a role in the initial 
process of reprogramming (Sridharan, et al., 2009). c-Myc has been found to 
accelerate cell-cycle progression by regulating the cyclin-Cdk complex (Amati, 
et al., 1998). Also, recent studies demonstrate its role in microRNA expressions 
regulating cell-cycle progression through key cell-cycle molecules cyclin D2 and 
p21 (Judson, et al., 2009; Lee, et aL, 2008; Wang, et al., 2008). In concert with 
Oct4, Sox2 and Klf4, downregulation of fibroblast specific gene, thyl was 
observed with the upregulation of embryonic markers such as alkaline 
phosphatase and stage-specific embryonic antigen-1 (SSEA-1) (Brambrink, et aL, 
2008; Stadtfeld, et al., 2008). 
In the early intermediate stage, the endogenous pluripotency genes, Oct4, 
Nanog and Sox2 were induced (Okita, et aL, 2007; Wemig, et al., 2008; Wemig, 
et aL, 2007; Brambrink, et al., 2008; Stadtfeld, et al., 2008). Furthermore, 
chromatin resetting, DNA methylation and histone modification are mediated 
partially by proliferation. The relaxation of chromatin structure allows the 
exogenous pluripotent factors, Sox2, Oct4 and Klf4 to access and establish the 
self-sustainable pluripotency network. Oct4 and Sox2 dimerize and co-occupy, 
often together with Klf4, the promoter region of several pluripotency factors 
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including their own promoters (Boyer, et al., 2005; Kim, et al.’ 2008; Masui, et 
al., 2007). Histone methylation reestablishes pluripotency, by restoring the 
global histone methylation patterns to ES cell-like state. The Oct4, Sox2 and 
Nanog recruit polycomb group proteins, leading to gene expression alteration 
through histone methylations (Lee, et al, 2006). The Oct4 and Sox2 complex 
have also been found to directly regulate the transcription of several chromatin-
remodeling factors such as histone demethylases (Loh, et al., 2006; Loh, et al., 
2007). 
In the later intermediate stage, the viral exogenous factors were silenced 
by the upregulation of de novo DNA methylatransferase DnmtSa and DnmtSb 
regulated by Oct4, Sox2 and Nanog along with other transcription factors 
(Sinkkonen, et al., 2008). Thus they established the self-sustainable pluripotency 
network. 
In the latter stage, ES-cell like histone methylation patterns resulted, and 
the inactive X chromosome in female cells was reactivated through repression of 
Xist by the binding of core pluripotency transcription factors, Oct4, Nanog and 
Sox2, to the Xist locus (Do, et al., 2008; Maherali, et al., 2007). 
Finally, the generated iPS cells should be capable of giving rise to new 
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Figure 1.1 The kinetics of major events in the reprogramming process in 
mouse embryonic fibroblast (MEF) 
After viral-transduction of four transcription factors, alkaline phosphatase (AP) 
and SSEA-1 positive cells were detected 3 and 9 days, respectively. The Oct4 
and Nanog activation were observed after 2 weeks. The viral transduced factors 
expression was necessary for about 2 weeks to initiate the reprogramming 
process. After the initiation of pluripotency loci, the exogenous expression of 
transciption factors was silenced and the pluripotent state developed, induced 
pluripotent stem cells generated. (Brambrink, et al., 2008; Stadtfeld, et al, 2008). 
(Diagram was modified and redrawn from Jaenisch and Young, 2008) 
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1.3.3 Gene delivery systems for ips cell generation 
In the beginning of the generation of induced pluripotent stem cells, 
MMLV (Moloney murine leukemia virus) retrovirus transduction was used to 
introduce the transcription factors. The MMLV promoter is usually silenced in 
pluripotent state in iPSC. 
However, the retroviral-mediated gene delivery is limited to active 
dividing cells and the stable integration of retroviral DNA in the host genome 
leads to genomic alterations and possibly causes cancer. Moreover, reactivation 
oftransgenes was often observed in differentiated cells, which drove the c-Myc 
expression and subsequent induction of tumors formation in iPS-cell-derived 
chimeric mice. 
Therefore, several non-integrating methods including plasmids transient 
transfection, nonintegrating adenovirus and episomal vectors were used to 
generate iPSC, albeit low reprogramming efficiency and risk of transgene 
insertions into the target cell genome (Stadtfeld, et aL, 2008; Zhao, et al, 2009; 
Okita 2008; Yu, et al., 2009). 
Excisable approaches using Cre-loxP (Soldner, et al., 2009; Kaji, et al., 
2009) and transposon (Yusa, et al., 2009) were applied after reprogramming, but 
residual genes continue to pose the safety concern. 
The use of DNA in reprogramming process inevitably poses threats on 
insertional mutagenesis, non-DNA methods were established and proven 
successful in reprogramming. 
The use of purified recombinant reprogramming proteins fused with a 
poly-arginine cell transduction domain was shown effective in generating iPSC 
from fibroblast except low efficiency (Zhou, et al., 2009; Cho, et al” 2010). 
Other than protein, RNA is another approach for non-DNA 
reprogramming. Synthetic modified mRNA and microRNAs were used. 
Synthetic modified mRNA, synthesized mRNAs with 5-methylcytidine (5mC) 
for cytidine or pesudouridine (psi) for uridine to generate pluripotent stem cells 
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without altering the genetic material of cells and the resulting stem cells 
recapitulated the functional and molecular properties of stem cells (Warren, et al, 
2010). 
MicroRNA is non-coding RNA to suppress the translation of target 
mRNA. Mir-302, predominantly expressed in stem cells and iPSC but not 
differentiated cells, mainly targets the transcripts of developmental signals and 
oncogenes (Lin, et al., 2008). It is able to induce reprogramming though the 
suppression of epigenetic regulators (Lin, et al, 2011; Zhong, et al, 2010). 
Finally, attempts were made to replace the reprogramming factors with a 
cocktail of defined small molecules to induce or enhance reprogramming. The 
use ofKlf4 and c-Myc was replaced by valproic acid, a histone deacetylase 
inhibitor (HuangfU, et al., 2008). Sox2 and c-Myc were replaced by BIX-01294, a 
histone methylatransferase (Shi, et al., 2008). However, the complete 
replacement of transcription factors is not yet successful, and the long-term 
effects of such molecules on epigenetic alterations have not been investigated. 
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1.3.4 Culture system for embryonic stem cells and iPSC 
1.3.4.1 Feeder and serum used cell culture system 
When ESCs were first isolated, they were cultured in feeder, the mitotic-
inactivated embryonic fibroblast cells, to maintain their pluripotency (Evans and 
Kaufman, 1981; Martin, 1981). After the discovery of leukemia inhibitory factor 
(LIF), ESCs are able to maintain undifferentiated in ES medium without the use 
of feeder in the gelatin-coated culture vessels (Smith, et al., 1988; Williams, et 
al.，1988; Niwa, et al., 1998). However, it is still a common protocol to 
propagate ESCs on feeder cells with serum and addition of LIF (Shimizukawa, et 
al, 2005; Ying, et al., 2003a; Fok and Zandstra, 2005). 
The culture condition with the use of growth-inactivated feeder cells and 
serum are regarded as poorly defined. The condition of feeder cells is important, 
usually only early passages of MEFs are used to prevent ESC differentiation. 
Also, the serum used for ESCs growth is always under stringent batch screening 
to ensure no factors present to induce differentiation of ESC. This creates batch-
to-batch variability. Therefore, feeder-free, serum-free culture system was 
established. 
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1.3.4.2 Serum-free culture condition 
With the discovery of derivation of mESC on gelatin in the absence of 
feeders and additional growth factors (Ying, et al., 2008), the use of knockout 
serum replacement with differentiation pathway inhibitors was established. 
It was reported that the used of knockout serum replacement instead of 
fetal bovine serum greatly facilitates mouse ESC derivation (Cheng, et al., 2004; 
Nichols, et al., 2009), thus it has been reported iPSC can be derived under 
serum-free conditions (Stadtfeld, et al., 2008; Wemig, et al., 2008) and improved 
the reprogramming process of mouse embryonic fibroblast resulted (Blelloch, et 
al., 2007) 
The serum-free condition improves the reprogramming efficiency may 
result from the addition of inhibitors that support the mESC self-renewal and 
pluripotency. The use of GSK3 (glycogen synthase kinase 3) inhibitors 
CHIRON99021, ERK (extracellular signal-related kinase) inhibitors PD184352 
and LIF in serum free condition inhibit the differentiation-associated pathways. 
Inhibition of differentiation-associated pathways has been shown important in 
inducing pluripotency, and treatment of partially reprogrammed iPSC with 
inhibitors facilitated their efficient conversion into fully reprogrammed iPS cells 
(Silva, et al., 2008). Interestingly, the inhibition of differentiation seems to be 
important also during normal germ cell development (Surani, et al., 2007). 
29 
1.3.5 Differentiation potential of iPSC 
1.3.5.1 In vitro stringency tests 
The iPSC can be cultured in vitro and differentiated with the use of 
existing protocols for embryonic stem cells. These protocols have been used to 
differentiate iPS cells, giving rise to cardiomyocytes (Schenke-Layland, et al., 
2008; Martinez-Fernandez, et al., 2009; Mauritz, et al., 2008; Narazaki, et al., 
2008; So, et al, 2010), adipocytes and osteoblasts (Tashiro, etal., 2009), 
hematopoietic and differentiated blood cells (Niwa, et al., 2009), dendritic cells 
and macrophages (Senju, etal, 2009), insulin-producing cells (Maehr, et al., 
2009; Tateishi, et al, 2008; Zhang, et al., 2009), hepatocyte-like cells (Si-Tayeb, 
et al., 2010a; Song, et al., 2009), retinal cells (Buchholz, et aL, 2009; Meyer, et 
al., 2009; Osakada, et al, 2009) and several types of neurons (Karumbayaram, et 
al, 2009; Dimos, et al., 2008; Ebert, et al.’ 2009). 
The spontaneous in vitro differentiation provides a qualitative assessment 
that suggests the possibility of multiple lineages differentiation. However, it is 
not definitively proven the acquisition of functional pluripotency. 
1.3.5.2 In vivo stringency test 
To test the quality of ESC, injection of cells into subcutaneous tissue of 
immunodeficient mice allows the self-assembly of differentiating tissues and 
promotes the teratoma formation containing three germ layers. Therefore, to test 
the differentiation potential of iPS cells, similar test is often used (Hentze, et al., 
2009). 
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1.3.5.3 In utero stringency test 
Pluripotent iPS cells from animal sources must recapitulate embryonic 
stem cell functions throughout development (Nelson, et aL, 2009). For mouse 
iPS cells, they are incubated with eight-cell embryos (morula) or injected into a 
blastocyst and transferred back into the uterus of a stage-appropriate surrogate 
mother. If nuclear reprogramming has been successftil, iPS cells will integrate 
and populate the developing embryo to generate iPS-cell-derived tissue in the 
chimeric offspring. Healthy pluripotent cells will contribute not only to the 
developing tissue, but also to the specialized germ cells that are capable of 
germline transmission to naturally bred offspring (Nagy, et al., 2010). 
In addition, iPS cells from mouse have been tested in tetraploid 
aggregation experiments. The entire embryo is derived from iPS cells when host 
embryo is only competent to give rise to extraembryonic tissues. The resulting 
live-birth offsprings are genetically identical to the transplanted iPS cells, thus 
demonstrating an autonomous capacity to undergo embryogenesis (Zhao, et al., 
2009). 
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1.4 Mouse Lewis lung carcinoina-D122 
D122 is the metastatic clone of Lewis lung carcinoma (3LL), which 
originated spontaneously in a C57BL/6J(H-2b) mouse. It can produce 
spontaneous lung metastases (Eisenbach, et al, 1983). 
D122 is a highly metastatic, weakly immunogenic Lewis lung carcinoma 
clone which expresses very low levels ofH-2Kb and can grow as local tumors 
across allogeneic barriers (Eisenbach, et al, 1984; Plaksin, etaL, 1992). This 
clone has been extensively studied in immimotherapeutic studies (Porgador, et 
al, 1993; Carmon, et al., 2000; Goldman, et al, 2000; Kawarada, et al., 2001; 
Pan, et al., 2005; Ramirez, et al., 2006; Xia, et al., 2006; Zhu, et a!., 2006; 
Garrido, et al., 2007; Labrada, et al, 2010). 
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Figure 1.2 Morphology of mouse Lewis carcinoma D122 
Phase contrast image of D122 
(Magnification : xlOO) 
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1.5 Dendritic cell vaccine in cancer immunotherapy 
The classical cancer treatments such as surgery, chemotherapy, radiation 
and hormonal treatment are effective in early stage of cancer. However, it is 
ineffective in treating metastatic tumor and causes severe side effects. Therefore, 
alternative treatment strategies are in great demand. 
Early experiments of immunization with chemical or virally induced 
tumors to stimulate tumor-specific responses which could reject the original 
tumors upon re-challenge, demonstrated that the immune system is able to 
suppress cancers. This appraoch is named as cancer immunotherapy (Old and 
Boyse, 1964, Klein, 1966). 
Cancer immunotherapy, is the activation the patients' own immune 
system to combat cancer. Cytotoxic T-cell (CTL) is responsible for killing tumor 
cells (Sallusto and Lanzavecchia, 2002). However, the destruction of tumor cells 
by cytotoxic T cells requires stimulation and antigen presentation by antigen 
presenting cells (Bennett, et al., 1997). 
Dendritic cells are the most potent antigen presenting cells (Banchereau 
and Steinman, 1998). One DC is sufficient to turn on 100-3,000 T cells 
(Bhardwaj, et al., 1993). It plays a critical role to induce, sustain and regulate 
responses of naive T cells (Steinman and Banchereau, 2007; Melief, 2008). DC 
presents the processed tumor associated antigens (TAA) to the major 
histocompatibility (MHC)-encoded molecules expressed on the cell surface. 
With the appropriate co-stimulatory molecules on the cell surface, CTLs priming 
take place. CTLs proliferate and kill any cells having the same antigen presented 
on the DC membrane (Banchereau and Steinman, 1998). DC also activates 
natural killer cells (Fernandez, et al., 1999) and natural killer T cells (Fujii, et al., 
2002). So, DC can conduct all the elements of the immune orchestra, which is an 
attractive target and tool for cancer immunotherapy. 
However, the efficacy of cancer immunotherapy using DC highly 
depends on the DC manipulation (O'Neill, et al., 2004, Steinman and Banchereau, 
2007, Banchereau and Palucka, 2005). Numerous reports have shown different 
ways to manipulate DC, including loading DC with tumor cells lysates 
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(Asavaroengchai, et aL, 2002), tumor antigenic protein or peptides (Prins, et al., 
2003)，viral vectors (Zhang, et al., 2003), DNA or RNA encoding antigen and 
tumor/ dendritic hybrid (Trefzer, et al., 2004, Zhang, et al., 2006b). These 
approaches showed that manipulated dendritic cells are able to enhance the 
efficacy in cancer immunotherpay. 
Moreover, the first therapeutic cancer vaccine Sipuleucel-T approved by 
U.S. FDA (Buonerba, et al., 2011) is an autologous, dendritic cell-based vaccine 
to treat castration-resistant prostate cancer patients. Ninety-nine percent of 
prostate cancer cells expressed prostatic acid phophstase (PAP), a prostate 
specific antigen and prostate-specific membrane antigen. Dendritic cells of 
patient were collected and recombinant form of PAP with GM-CSF were loaded 
ex vivo. Prostate cancer patients immunized with Sipuleucel-T resulted in 
improved survival time. 
The in vivo transfer of dendritic cells has proven efficient in the T cells 
priming and provided anti-cancer immunotherapy. However, to elicit an effective 
immune response, suitable antigen and strategies to load antigens for dendritic 
cells recognition are crucial. 
With the development of generation of induced pluripotent stem cells, 
induced pluripotent stem cells are generated from cancer cells after introduction 
of transciption factors, Oct4, c-Myc, Sox2 and Klf4. Moreover, the cancer 
specific oncogene, like BCR-ABL in chronic myeloid leukemia cells, expressed 
after the reprogramming (Carette, et al., 2010). 
34 
1.6 Green Fluorescence protein Reporters 
1.6.1 GFP reporters in embryos and stem cells 
GFP has been used in numerous applications, as a reporter molecule to 
study gene expression, protein trafficking and localization (Chalfie, et al., 1994), 
as a marker of transfection (Lamm, et al., 1997) or to follow morphological 
changes of apoptotic cells. 
There are numerous reports on the use of green fluorescent protein (GFP) 
as a reporter to monitor reprogramming and assess the efficiency (Takahashi & 
Yamanaka 2006). GFP has been used extensively in early embryonic 
development in embryonic stem cells. In 1995, it was demonstrated that EGFP 
could function as a reporter in transgenic mouse embryos (Ikawa, et al., 1995). 
GFP can be used to measure quantitative gene expression, as the intensity of 
GFP fluorescence is directly proportional to mRNA abundance (Soboleski, et al., 
2005). Nanog or Oct4 reporter has been shown to be an efficient tool to select 
reprogrammed clones (Okita, et al, 2007) and monitor the undifferentiated state 
(Eiges, et flf/., 2001). 
1.6.2 copGFP 
The copGFP protein is a novel natural green monomeric green 
fluorescent protein cloned from copepod Pontellina plumata, a type of plankton 
(Wilmann, et al., 2006). The copGFP protein is a non-toxic, non-aggregating 
protein with fast protein maturation, high stability at a wide range of pH (pH 4-
12), and fluorescent properties that do not require any additional cofactors or 
substrates. Due to its exceptional properties, copGFP is an excellent fluorescent 
marker that can be used instead of EGFP (the widely used Aequrea victoria GFP 
mutant) for monitoring delivery of FIV constructs into cells. The copGFP protein 
has a very bright fluorescence that exceeds the brightness of EGFP by 
approximately a third. 
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1.7 Aim of study 
The aim of this study is to demonstrate whether a mouse Lewis lung 
carcinoma can be reprogrammed into induced pluripotent stem cells. My 
hypothesis is that transformed cells remain amenable to reprogramming using the 
Yamanaka's factors, and such reprogrammed cells are capable of differentiation 
into different cell lineages. 
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Chapter II Materials and Methods 
2.1 Materials 
2.1.1 Primers used in polymerase chain reaction (PCR) 
Table 2.1 Primers used in PCR 
I Gene | Sense | Primer sequence | Source Tm Size Remarks 
Pluripotent genes 
1 Oct4-T Forward 5‘-gttggagaaggtggaaccaa-3 ‘ (Kaji, g, 57°C 6 1 b p q R T - P C R 
(Pou5fl) Reverse _ 5,-ctccttctgcagggctttc-3, «/.’2009) 
~2 Klf4-T Forward “ 5‘-cgggaagggagaagacact-3‘ (Kaji, et 60°C 62bp qRT-PCR 
Reverse 5'-gagttcctcacgccaacg-3' 口广‘勘今) 
"3 MycT-2 Forward 5‘-cctagtgctgcatgaggaga-3 ‘ (Kaji, et60°C 72bp qRT-PCR 
Reverse 5 ’-tcttcctcatcttcttgctcttc-3 ’ ，2009) 
"4 S o x 2 T - 2 F o r w a r d 5'-acagctacgcgcacatga-3‘ (Kaji, et60°C 69bp qRT-PCR 
Reverse 5,-ggtagcccagctgctcct-3, ，之。。9) 
~5 Myc-endo Forward “ 5‘-tcaagcagacgagcacaagc-3 ‘ (Kaji, er 60°C 242bp qRT-PCR 
Reverse 5 ‘-tacagtcccaaagccccagc- 3, “乙’ 2009) 
~6 Klf4-endo Forward 5‘-ggcgagaaaccttaccactgt-3 ‘ (Kaji, et 57°C 226bp qRT-PCR 
Reverse 5 ‘ -tactgaactctctctcctggca-3 ‘ "/"^oog) 
~7 Oct4-endo Forward _ 5,-ccaacgagaagagtatgaggc-3’ （Kaji, 57°C 308bp qRT-PCR 
Reverse 5,-gtgcttttaatccctcctcag-3’ a/.，2009) 
~8 Sox2-endo “ Forward “ 5'-tctgtggtcaagtccgaggc-3' (Kaji, 60°C 254bp qRT-PCR 
Reverse 5 ‘-ttctccagttcgcagtccag-3' 2009) 
~9 N a n o g - a F o r w a r d 5’-cctccagcagatgcaagaa-3’ (Kaji, 60°C 364bp qRT-PCR 
Reverse 5' -gcttgcacttcatcctttgg-3 ‘ a/‘’ 2009) 
"To Utfl-a Forward 5' -gtccctctccgcgttagc-3 ‘ (Kaji, et 60°C 87bp qRT-PCR 
Reverse 5,-ggggcaggttcgtcattt-3, 口人'2009) 
~Tl D p p a 5 - a ^ Forward “ 5'-attcgggctaaatggatgc-3‘ (Kaji, 60°C 102bp qRT-PCR 
Reverse 5,-tagctccagggtcttcatgg-3， � ^ ’ 2009) 
~12 Dppa4 Forward 5'-aagggctttcccagaacaat-3 ’ (Kaji’ 57°C 132bp qRT-PCR 
Reverse 5 ‘ -tccagaggaactgtcacctca-3' < 2009) 
"13 Dppa3 Forward “ 5'-gatgcacaacgatccagattt-3‘ (Kaji, 57°C 108bp qRT-PCR 
Reverse 5 ‘ -tggaaattagaacgtacatactccaa-3 ‘ 以人’ 2 0 0 9 ) 
~14 E i ^ Forward 5‘-gcccctcatcagactgctac-3 ‘ (Kaji, er 60°C 66bp qRT-PCR 
— , . ,, a/., 2009) 
Reverse 5 -gcagctcaaggaagaggtgt-3 
~15 Esrrb Forward 5,-tggcaggcaaggatgacaga-3’ （Kaji, 60°C 223bp qRT-PCR 
Reverse 5，-tttacatgagggccgtggga-3' < 細；) 
1 6 G ^ Forward "5'-gctgctcgctttctctgc-3' (Kaji,过 60°C 145bp qRT-PCR 
Reverse 5 ‘-gctgtaatccacatcgctctc-3, < 2009) 
~V7 R ^ Forward 5’-ggaagaaatgctgaaggtggagac-3' (Kaji," 57°C 250bp qRT-PCR 
Reverse 5'-agtccccatccccttcaatagc-3' 口,.’ • Q ) 
1 8 ^ Forward “ 5‘-ctaaaggcgcatctgcgta-3 ‘ (Kaji,召, 57°C 104bp qRT-PCR 
Reverse 5,-tagtggcgggtaagctcgt-3' al； 2009) 
~19 T^n Forward 5，-gcttcctctctgggtgttca-3, (Kaj“， 57°C 219bp qRT-PCR 
Reverse 5 ‘-cccacacattccctttcaac-3, al； 2009) 
DnmtSl Forward 5'-caactacccgcttccttcag-3’ (Kaji, e/ 57°C 78bp qRT-PCR 
Reverse 5，-cccgcatagcattctggta-3, ",，彻今) 
~Y\ Ecatl Forward 5’-ggcgagctgagatttggata-3’ (Kaji,�/ 6 0 � C 121bp qRT-PCR 
Reverse 5' -ccagcctccagagcctctat-3, < 溯^) 
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Gene | Sense Primer sequence Source Tm Size Remarks 
Methylation study 
I MeNanog- Forward 5'-gattttgtaggtgggattaattgtgaattt-3‘ ( T a k a i ^ 5 8 ° C 367bp KAPA 
F2 Reverse 5'-accaaaaaaacccacactcatatcaatata-3' 2006) 
House keeping gene 
b-actin Forward 5 ‘-gctctggctcctagcaccat-3 ‘ (Sasaki, e t 6 0 � C 75bp qRT-PCR 
Reverse 5 ‘-gccaccgatccacacagagt -3， 礼擺今) 
t ^ Forward 5'-ggggagctgtgatgtgaagt-3 ‘ (Kaji,"«/.’ 57°C 93 bp qRT-PCR 
Reverse 5 '-ccaggaaataattctggctcat-3， 細9) 
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2.1.2 DNA clones used in the study 
Name Source Remarks Antibiotics 
pPyCAG-Nanog-IP~Addgene 13838 (Mitsui, et al, Ampicillin 
2003) 
pCAG2LMKOSimO Addgene 20866 (Kaji, etal, Ampicillin 
2009) 
2.1.3 Materials for DNA manipulation 
Chemicals and Enzymes Manufacturers Catalog No. 
Agarose Invitrogen (Carlsbad, 15510-027 
C^ 
DNA MW marker Ikb ladder Invitrogen (Carlsbad, 10787-018 
C^ 
^ A P A 2 G Fast HotStart Polymerase KAPA Biosystems KK5501 
Platinum Pfic DNA Polymerase Invitrogen (Carlsbad, 11708-013 ^ 
lOOmM dNTP Set Invitrogen (Carlsbad, 10297-018 
C^ 
Micro Amp Optical 3 84-Well React ionAppl ied Biosystem 4309849 
Plate with Barcode 
"Optical Adhesive Covers Applied Biosystem 4360954 
Fast Start Universal SYBR Green Roche 04913850001 
Master Mix (Rox) 
"Pvul Invitrogen 25420-118 
2.1.4 Materials for RNA manipulation 
Chemicals and Enzymes Manufacturers Catalog 
N o 
RNA superscript ®III Reverse Invitrogen (Carlsbad, 18080-044 
transcriptase CA) 
Oligo (dT) 12-18 Primer Invitrogen (Carlsbad, 58862 
CA) 
RNaseOUT • Recombinant Invitrogen ( C a r l s b a d , 1 0 0 0 0 0 8 4 0 
Ribonuclease Inhibitor CA) 
Total RNA-murine embryonic stem cells Cell Biolabs (San CBA-304 
line D3 Diego, CA) 
39 
2.1.5 Antibodies 
r ^ t i b o d i e s I Manufacturers I Catalog No. 
Monoclonal antibodies 
Oct3/4 STEMGENT 09-0023 
Nanog STEMGENT ~ ~ 09-0020 
SSEA-1 STEMGENT 09-0005 
PAX6 — Developmental Studies NA 
Hybridoma Bank 
Rat-401 (Nestin) Developmental Studies NA 
Hybridoma Bank 
Secondary Antibody 
Alexa Fluor 568 rabbit anti mouse IgG Invitrogen (Carlsbad, CA) A11061 
(H+L) 




l ^ t s Manufacturers Catalog No. 
Rneasy mini kit (50) Qiagen Inc. (QIAGEN 74104 
GmbH, Hilden) 
QIAfilter TM Plasmid Midi Qiagen Inc. (QIAGEN 12243 
Kit (25) GmbH, Hilden) 
Cell line nucleofector kit V Lonza VGA-1003 
(25RCT) 
MEF2 Nucleofector Kit Lonza VPD-1005 
StemgentTM Alkaline STEMGENT 00-0009 
Phosphatase Staining Kit 
Cell line optimization Lonza VCO-1001 
nucleofector Kit 
Alkaline Phosphatase Millipore SCR004 
Detection Kit 
EpiTect Bisulfite Kit Qiagen 59104 
QIAquick Gel Extraction Kit Qiagen 28706 
pGreen Zeo TM-mNanog System Biosciences SR10031VA-1 
Transcriptional Reporter Virus 
(packaged) L 
2.1.7 Bacteria strain and culture reagents 
2.1.7.1Bacteria culture reagents: 
Products Manufacturers Catalog No. 
LB Broth Invitrogen 12780-052 
Kanamycin sulfate Invitrogen 11815-032 
Ampicillin Sodium Pamecil HK-34597 
2.1.7.2 Bacterial strain used for transformation 
One shot (R) TOP 10 Chemically Competent Invitrogen 
E.Coli 
DH5 alpha (kindly provided by Lau 
KM,s group) 
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2.1.8 Culture media and reagents: 
2.1.8.1 General culture media and reagents 
Products Manufacturers Catalog No. 
DMEM “ Invitrogen (Carlsbad, CA) 11965092 
Fetal bovine serum Gibco 26140-079 
0.5% Trypsin-EDTA "Gibco — 15400-054 
PBS pH 7.4 (IPX) " ^ c o 70011 
Gelatin Sigma G7041 
Trypan Blue Solution (0.4%) Sigma T8154 
Dimethyl Sulfoxide Sigma D-8428 
Lipofectamine 2000 Invitrogen (Carlsbad, CA) 11668019 
Geneticin Invitrogen (Carlsbad, CA) 11811-031 
Zeocin liMtrogen (Carlsbad, CA) 11006-330 
Mitomycin C (2mg) M4287 
BCIP Gibco BRL Y01161 
NBT Gibco BRL Y01162 
2.1.8.2 Traditional ES medium 
Traditional ES medium (serum and feeder layer required) 
Products ~ Manufacturers Catalog 
^ 
KnockOUT DMEM Gibco 爾 2 9 
ES cell FBS (meets USDA import Gibco 10439-024 
requirements, Mexico origin) 
lOOX L-glutamine Gibco 25030-024 
lOQX Pen/Strep Gibco 15140-122 
IQOX non-essential amino acids Gibco 11140-050 
lOOX EmbryoMax ES cell Qualified 2- Millipore ES-007-E 
Mercapethanol 
lOOX EmbryoMax ES cell Qualified Millipore ES-008-D 
Nucleosides 
ESGRO LIF Millipore ESG1106 
2.1.8.3 Feeder-free serum-free medium 
Products Manufacturers Catalog No. 
ESGRO Complete Plus Clonal Grade Millipore SF001-500P 
medium 
Accutase Millipore SF0Q6 
" ^ G R O Complete Basal Medium Millipore SF002-500 
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2.1.9 Cell line used 
Name Origin Culture condition 
D122 DMEM10% FCS “ 
MEF Homemade DMEM 15% FCS 
" S ^ CBA-316(Cell BioLabs) DMEM 10% FCS 
SNL feeder cell line derived 
from mouse fibroblast STO cell 
line transformed with neomycin 
resistance and murine LIF 
genes. 




Electroporator System (The Nucleofector device) Amaxa Biosystems 
ABI 7900HT Real-time PGR — Applied Biosystem 
C1000 thermal cycler Bio-Rad 
LEICA DMIRB Research Inverted microscope Leica 
FACSCalibur Becton Dickson 
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1 Routine cell culture 
All cell lines were maintained at 37°C with 5% CO2. Culture medium 
was changed twice a week and subcultured when 80% confluence. 
2.2.1.2 Resuscitation and culture from frozen stock 
To thaw cells, a cryovial was taken from the liquid nitrogen and put on 
37�C water bath. When only a small ice crystal remained, the surface of cryovial 
was disinfected using 70% ethanol. Cells were transferred from the cryovial to 
the 15 ml centrifuge tube, pre-warmed cell culture medium was added dropwise 
and then centrifuged at 800 rpm for 4 mins. Supernatant was aspirated, 
resuspended in culture medium and washed twice. Cell pellet was resuspended in 
culture medium and incubated overnight. Medium was changed after 24 hours to 
remove trace of DMSO. 
2.2.1.3 Passage of cells 
Cells were passaged according to their confluency. Briefly, culture 
medium was aspirated and cells were washed once with PBS. Subsequently, 
sufficient amount of pre-warmed trypsin was added to cover the culture surface 
and incubated at 37°C incubator for 5 minutes. Five-fold volume of culture 
medium with respect to trypsin was added. Cells were pipetted up and down to 
obtain single cell suspension. Cells were centrifuged at 800 rpm for 4 minutes at 
room temperature. The supernatant was aspirated and resuspend in culture 
medium. The cells were split in 1:5 ratios generally. 
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2.2.1.4 Cryopreservation of cells 
To freeze cells, 2*10^ cells were pelleted and cryopreserved in Ix-
freezing medium, pipetting up and down gently, placed in cryovials. The 
cryovials were stored at -80�C in a Cryo 1° freezing container from Nalgene 
filled with isopropanol guaranteeing slow and gently freezing of cells. The 
cryovials were transferred into liquid nitrogen for long-term storage. 
2.2.1.5 Mouse ES cells culture 
For long-term culture, mouse ESC and iPSC were grown on a layer of 
mitomycin C inactivated SNL feeder or under feeder-free condition in ESGRO 
medium on gelatin coated plate to maintain their undifferentiated state. 
2.2.1.5.1 Passage and maintenance of SNL 
SNL cells (Cell BioLabs) were passage as describe in 2.2.1.3. 
2.2.1.5.2 Inactivation and plating of SNLs (Feeder preparation) 
The 100 mm dishes were coated with 0.2% gelatin and incubated at room 
temperature for at least 2 hours. Mitomycin C in PBS (1 mg/ml) was diluted and 
filter-sterilized and media from SNLs was aspirated. Then 10 ml SNL medium 
containing 5 |ig/ml of mitomycin C was add on SNLs. After 5 hours incubation 
at 37�C，the mitomycin C containing media was removed and cells was washed 
twice with PBS, trypsinized, centrifuged and resuspended in SNL medium. Cells 
were counted and plated at 50000 cells/ cm� in 100mm dish for supporting ES 
cell growth. To ensure the SNLs were inactivated, cells were counted after 
overnight incubution. The cell number of SNLs before and after overnight 
incubation should not exceed 10% to ensure the inactivation was completed. 
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2.2.1.5.3 Cryopreservation (freezing) of SNLs 
Unused SNLs and mitomycin-inactivated SNLs would be cryopreserved 
for later use. Culture media was removed from the dish, cells were washed with 
PBS without Ca2+ Mg2+ and trypsinized for 5 minutes at 37°C. Trypsin was 
neutralized by added 10 ml ofMEF medium. Cells were centrifiiged at 800 rpm 
for 4 minutes. After centrifUgation，the supernatant was removed and the cells 
were resuspended in Ix freezing medium. The cell suspension was transferred 
into cryovial (1 ml per vial). Usually, 1*10^ was frozen per vial. Cryovial were 
placed in Cryo 1° freezing container from Nalgene filled with isopropanol 
guaranteeing slow and gentle freezing of cells. The vials were transfer to the 
liquid nitrogen tank for long-term storage. 
2.2.1.6 Mouse ES cells culture in feeder-free culture conditionsl 
2.2.1.6.1 Preparation of gelatin coated plates 
All culture plates were coated with gelatin before use. Add 1% gelatin 
solution to cover the culture plates and incubate at room temperature or at 37�C 
incubator at least one hour before use. 
2.2.1.6.2 Thawing mouse ES cells 
The vial with frozen CCB mESCs was removed from the liquid nitrogen 
and thawed in a warm water bath. When just a small crystal of ice remains then 
vial was sterilized with 70% (v/v) ethanol. Afterwards, the cell suspension was 
added into 10 ml of warm ES medium dropwise to reduce osmotic shock. Then 
centrifuge the suspension at 800 rpm for 4 minutes. Supernatant was removed 
and fresh medium was added to the cell pellet, resuspended and centrifiiged. 
Then the cell pellet was resuspended in 15 ml ESGRO medium and plated in 100 
mm dish. The media was replaced after 24 hours to prevent the remaining 
DMSO induced differentiation of ESCs. 
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2.2.1.6.3 Passage of mouse ES cells 
CCB mESCs were routinely cultured on gelatin-coated tissue culture 
plates in ESGRO medium. Media was changed daily and cells were passaged 
when approaching confluency. To passage CCB mESCs, accutase was used to 
dissociate mouse ES cells into single cell suspension. CCB mESCs were washed 
in phosphate buffered saline (PBS) followed by incubation in accutase for 2 mins 
at 37°C incubator. Then cells in accutase were pipetted into single cell 
suspension. Basal medium was added in single cell suspension and centrifliged 
for 4 mins at 800 rpm. CCB mESCs were split in 1:5 ratio and medium replaced 
twice a day. 
2.2.1.6.4 Freezing mouse ES cells 
To freeze cells, 2*10^ cells were pelleted and cryopreserved in Ix-
freezing medium, pipetting up and down gently, placed in cryovials. For ES 
freezing medium, LIF was added to maintained pluripotency of mouse ES cells. 
The cryovials were stored at -80°C in a Cryo freezing container from Nalgene 
filled with isopropanol guaranteeing slow and gently freezing of cells. The 
cryovials were transferred into liquid nitrogen for long-term storage. 
2.2.1.7 ES ceils differentiation-Formation of embryoid bodies (EBs) 
CCB mES cells were trypsinized and counted. Five hundred mESCs in 20 
ul mouse ES medium without LIF addition were transferred onto the cover of 10 
cm petri dish. Ten ml PBS was added in the petri dish to prevent desiccation. The 
suspension culture was kept for around 7 days until EBs formed. EBs were 
plated and cultivated in petri dish for additional 3 to 7 days in mouse ES medium 
with LIF addition. 
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2.2.1.8 Direct differentiation by retinoic acid 
To induce the spontaneous neuronal differentiation in iPS, lO'^M retinoic 
acid in DMSO was added in the mouse ES medium without LIF for four days. 
The neural-like cells appeared. 
2.2.1.9 Generation ofiPS Cells 
Fifty thousand D122_reNanog cells were nucleofected with 3 昭 
linearized OSKM plasmid (Addgene 20866) using nucleofector I I (Lonza) and 
switch the medium to ES medium on day 2 with (2 mg/ml G418) added. The 
medium was changed every day. After 9 days of nucleofection, the nucleofected 
cells were harvested and plated on mitomycin C-inactivated feeder layer. At day 
20, the colonies demonstrated high GFP expression were identified and 
mechanically picked for expansion. After expansion, colonies were cultured in 
ESRGO on gelatin-coated plate. 
2.2.2 Cell Transfection 
2.2.2.1 Lipofectamine 2000 transfection 
Fifty thousand cells/well were seeded in 6-well plate one day before 
transfection. After overnight incubation, cells were approximately 80% confluent. 
2 ml DMEM without FCS and antibiotics culture medium was replaced. For each 
6-well of cells, 4 \ig plasmid DNA was mixed with 10 \i\ lipofectamine in 500 |il 
DMEM without FCS and antibiotics respectively. After 5 minutes incubation, 
they were mixed and incubated at room temperature for 20 minutes to allow 
DNA-lipid complexation. Then the DNA-lipofectamine complexes were added 
to cell dropwise, followed by 6 hours incubation in 37。C incubator. Ten percent 
FCS were added to each well and medium changed after overnight incubation. 
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2.2.2.2 Nucleofection 
2.2.2.2.1 Optimization of nucleofection 
The nucleofection condition for D122 was optimized using Cell line 
optimization nucleofector Kit (Lonza) according to the manufacturer instructions. 
2.2.2.2.2 Nucleofection condition 
D122 cells were trypsinized counted. Fifty thousand cells were pelleted 
and resuspend in 100 ^il Solution V with 3 昭 plasmid. Program V-30 was used 
for nucleofection. Warm medium was added to the nucleofected cells and 
incubate in 37。C incubator overnight. 
2.2.3 Nucleic acid 
2.2.3.1 Genomic DNA isolation 
Cells were removed from tissue culture flask using trypsin. Cells were 
centrifuged at 800 rpm for 4 minutes. Supernatant was removed, cell pellet was 
resuspended in IX PBS and washed twice in IX PBS, centrifuged between 
washes. Then the pellet was resuspended in Proteinase K buffer with fresh 
Proteinase K (10 mg/ml) added. The mixture was shaken gently and incubated in 
37。C overnight. After overnight incubation, 1 volume of phenol: chloroform was 
added, mixed inverting up and down for 1 minute, and centrifuged at maximum 
speed for 15 minutes. The aqueous supernatant was removed carefully to a new 
tube. To precipitate DNA, 0.36-volume of 7.5M ammonium acetate and 2 
volume of 100% ice-cold ethanol were added to the aqueous supernatant. White 
DNA precipitated when shaken gently and centrifuged at maximum speed for 15 
minutes. Supernatant was removed and the cell pellet was by ice cold 70% 
ethanol with gently swirling. Low salt TE buffer was used to resuspend the air-
dried DNA pellet. The quality and quantity of genomic DNA was analyzed using 
NanoDrop and gel electrophoresis. 
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2.2.3.2 Restriction Enzyme Digestion 
Restriction Enzyme reaction mix (50 |il) was prepared as follows: 5 |xg 
Plasmid DNA, 5 |li1 lOX React? buffer, 0.5 \i\ lOOX BSA, 1 iiil restriction enzyme 
and constitute reaction mix to 50 |xl with mili.Q water. The reaction mixture was 
incubated at 37°C water bath for 4 hours and then heat inactivated at 65°C for 15 
minutes. Chroma Column was used to remove enzyme. The quality and quantity 
of digested plasmid DNA was analyzed using NanoDrop 1000 and gel 
electrophoresis. 
2.2.3.3 RNA and genomic DNA quantification 
The quality and quantity of RNA and genomic DNA was examined using 
NanoDrop. Two microlitre of sample was applied to the NanoDrop and 
measured. The OD260/OD280 value of for RNA and DNA was between 1.8 and 
2.0. 
2.2.3.4 Reversed transcription polymerase chain reaction (RT-PCR) 
2.2.3.4.1 RNA isolation and Reverse transcription (RT) 
Total RNA was purified using RNeasy kit (Qiagen) according to 
manufacturer instruction. Two micrograms total RNA was used for reverse 
transcription reaction using RNA superscript I I I Reverse transcriptase 
(Invitrogen) and Oligo dT (Invitrogen). Each 20 |li1 RT reaction mix consisted of 
11 fxl RNA sample dissolved in DEPC-treated water, 1 |xl reverse transcriptase, 
1 |Lil lOmM dNTP, 1 O.IM DTT and 1 \i\ RNaseOUT ™ Recombinant 
Ribonuclease Inhibitor. The reaction was conducted at 65°C for 5 min, 50。C for 
60 min, a denaturation step of 70°C for 15 min, and a final holding temperature 
of4。C. 
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2.2.3.4.2 Polymerase chain reaction (PCR) 
KAPA2G Fast HotStart Polymerase 
IX Reaction mixture: 
5X PCR buffer I 5 |li1 ~ 
MgCh (25 urn) " U d ~ 
dNTPs (2.5 urn) 1 — 
Forward primer (10 pmol) 0.5 fxl 
Reverse primer (10 pmol) 0.5 \i\ 
Tag polymerase 0.1 |xl 
Water 16 |li1 
Template 1 M-1 
Total volume 25 
Table 2.2 Reaction mixture ingredients for PCR reaction 
Master Mix was prepared for PCR reactions. After addition of template in 
the reaction mixture, the following program was used. 
Heat Denaturation 95°C 1 minute 
Denaturation 95°C 一 10s 
Annealing Specific temperature 10s 
(refer to table 2.1) 
Extension 72。C — Is 
Final extension 72°C 30s 
Table 2.3 Reaction Conditions for PCR reaction 
After mixing the reaction components, enzyme was first activated at 
95。C for 1 min. The general PCR condition was: denaturing at 95°C for 1 minute, 
annealing at specific temperature for 10 seconds. The specific annealing 
temperatures for different primers were shown in the table 2.1, extending at 72°C 
for 1 second. The above condition were repeated for 35 cycles and then 
terminated at 72°C for 30 seconds. 
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2.2.3.4.3 Real time polymerase chain reaction (qRT-PCR) 
Real-time quantitative PGR was performed using the Applied Biosystem 
7900 machine. Reactions were performed in 10 |xl reaction volumes using the 
SYBR Green Master Mix (Roche), and the standard cycler program with 
dissociation curve generated. Master Mix was prepared for n+1 reactions. 
Ix Reaction mixture: 
SYBR Green Master Mix 5 |xl 
(Tag included) 
Forward Primer (10 pmol) 0.5 |iil 
Reverse Primer (10 pmol) 0.5 |il 
PCR-grade water 3 |xl 
Template 1 |xl 
"Total volume | 10 |li1 
Table 2.4 Reaction mixture ingredients for qRT-PCR reaction 
Master Mix was prepared for qRT-PCR reactions. After addition of 
template in the reaction mixture, the following program with dissociation was 
performed. 
Trewarm SCFC 2 minutes 一 
Heat Denaturation 95°C 10 minutes 
Denaturation 95°C 15s 
Extension 60。C 1 minute 
Dissociation 95。C 15s 
60OC 15s 
Table 2.5 Reaction Conditions for qRT-PCR reaction 
After mixing the reaction components, enzyme was first prewarm at 50°C 
for 2 minutes, then activated at 95。C for 10 minutes. The general PGR condition 
was: denaturing at 95°C for 15 seconds, extending at 60。C for 1 minute. The 
above condition was repeated for 40 cycles followed by dissociation at 95°C for 
15 seconds and 60。C for 15 seconds, 1。C dropped for each cycle and 15 cycles 
dissociation were performed. Single peak on the dissociation curve confirms the 
primer is specific and no non-specific amplification. 
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2.2.3.5 Agarose gel electrophoresis 
RNA and DNA quality control was determined using agarose gel 
electrophoresis and ethidium bromide staining, 1.5 % gel and IX TBE buffer 
was used. Samples were loaded with 6x loading buffer and gels were run in an 
electrophoresis chamber at 120 V. Nucleic acids were visualized with UV light 
and photos would be taken for record. 
2.2.3.6 Genomic PCR for bisulfite sequencing 
Genomic DNA was isolated as described above. Bisulfite treatment was 
performed using EpiTect Bisulfite Kit (Qiagen) according to manufacturer 
instruction. The bisulfite converted DNA was amplified using KAPA polymerase 
(KAPA Biosystems). The amplified PCR product was cloned into pCR4 vector 
using TOPO TA Cloning kit (Invitrogen). Five randomly selected clones were 
sequenced with the M l 3 forward and Ml3 reverse primers for Nanog. The 
methylation status of the sequences were analyzed using BioQ Analyzer (Max-
Planck-Institut Informatik). PCR primers are listed in Table 2.1. 
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2.2.4 Bacteria and Plasmid preparation 
2.2.4.1 Preparation of competent cells 
For 250 ml of SOB broth, 0.5 ml of DH5 alpha bacteria was needed. The 
bacteria were incubated overnight at 37°C with 250 rpm shaking until 
OD600=0.4. Bacteria were harvested by centrifugation at 2500 rpm at 4°C for 
15 minutes. Al l residue SOB medium was drained and the pellet was washed by 
ice-cold Inuoe transformation buffer. Bacteria were centrifliged and resuspended 
in 25 ml ice-cold Inuoe transformation buffer for washing. Washing step was 
repeated twice and bacteria pellet was collected by centrifugation at 2500 rpm at 
4°C for 15 minutes. Pellet was resuspended in 10 ml ice-cold Inuoe 
transformation buffer and 750 |il DMSO was added. Bacteria suspension was 
mixed by gentle swirling and incubated on ice for 10 minutes. One hundred 
micro litre bacterial suspension was added to chilled, sterile eppendorf and snap-
frozen by immersing into bath of liquid nitrogen. The competent cells were 
stored at -70°C before use. 
2.2.4.2 Heat-shock transformation 
Three microlitre of ligation product/plasmid was added into each tube 
containing 100 |li1 of competent cells and incubate on ice for 15 minutes. The 
bacteria were heat-shocked in 42°C water bath for 30 seconds and put back on 
ice for 10 minutes. Two hundred and fifty microlitre pre-warm SOC medium was 
added and cells were incubated at 37°C for 30 minutes. Fifty microlitre 
transformed bacteria were used for plating on suitable LB agar with antibiotics. 
The plate was incubated at 37°C overnight. 
2.2.4.3 Midi prep of plasmid 
A colony of bacteria was picked and expanded in 100 ml of LB Broth 
containing suitable concentration of antibiotics at 37°C with 250 rpm shaking 
overnight. Bacteria were collected by centrifugation and plasmid extraction 
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performed using Qiagen Midi-prep according to manufacturer's instructions. The 
quality and quantity of plasmid DNA was analyzed using NanoDrop 1000 and 
gel electrophoresis. 
2.2.5 Cell staining 
2.2.5.1 NBT/BCIP Alkaline phosphatase staining 
Alkaline phosphatase staining was performed using NBT/BCIP (nitroblue 
tetrazolium and 5-bromo-4-chloro-3'-indolyl phosphate). For 1 ml reaction buffer, 
4.4 NBT and 3.3 |il BCIP solution was prepared fresh in 100 mM Tris buffer, 
pH 9.5. Cytospined cells on glass slide were fixed with acetone for 10 seconds. 
Freshly prepared NBT/BCIP solution was added for 30 minutes and washed in 
water for 10 minutes. Nuclear Fast Red was used to counter stained the nucleus 
in Red for visualization. 
2.2.5.2 Immunofluorescence 
Cells were fixed in 4% formalin in PBS for 15 mins, blocked in 3% BSA 
for 30 mins. Primary antibodies were incubated in 3% BSA overnight at 4。C. 
Secondary antibodies were incubated for 1 hour in room temp. Plates were 
washed 3 times for 15 mins in PBS after primary and secondary antibody 
incubations. Pictures were taken by LEICA DMIRB Research Inverted 
microscope (Leica). 
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2.2.6 Flow cytometry 
Ten thousands cells from each FASC tube were acquired on a FASC 
Calibur (Becton Dickson) and analyzed using CELLQuest software (Becton 
Dickson). GFP signals were acquired on the FL-1 channel using log 
amplification. 
For GFP fluorescence, the markers in the control histogram were set at 
the 95%. That brighter than 95% cells of control D122 cells were counted, the 
same marker set in the control histograms were used for the histograms which 
treated cells were analyzed. 
2.2.7 Mouse Strains and animal handling 
C57BL/6 mice were purchased from Animal Resources Center, Australia 
and maintained at the Laboratory Animal Service. 
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Chapter III Result 
3.1 Generation of Nanog-reporter-GFP-D 122 (D122_reNanog) 
It has been shown that Nanog expression is key to maintenance of the 
undifferentiated state of ESC (Chambers, et al., 2003, Mitsui, et al., 2003; Loh, 
et al., 2006; Wu, et al., 2006). Nanog is completely inactivated in somatic cell 
lineages. Its reactivation in iPS cells is a crucial marker for complete 
developmental potential (Maherali, et al., 2007; Okita, et al., 2007; Wernig, et al., 
2007). Thus using Nanog-specific promoter in a GFP reporter construct offers 
reliable and convenient fluorescence tracking of undifferentiated cells capable of 
pluripotency. 
The pGreen Zeo™ mNanog Transcriptional Reporter (System 
Biosciences) used in this work is a lentiviral vector and confers simultaneous 
green fluorescence and Zeocin resistance if Nanog protein is expressed (Figure 
3.1). This reporter in lentivirus was transduced into mouse Lewis lung carcinoma, 
D122, and the transduced cells renamed as D122_reNanog. The transduced 
D122—reNanog cells should remain non-fluorescent, as Nanog was not expected 
to express in D122. 
To test the functionality of the reporter, some of the transduced D122 was 
further transfected with an expression vector of Nanog, pPyCAG-Nanog-IP 
(Addgene 13838), using lipofectamine 2000. The transfected cells were expected 
to show green fluorescence and resistant to zeocin selection. Two days after 
transfection, cells were collected and examined using fluorescence microscopy. 
The green fluorescent cells were observed, showing that the Nanog promoter 
reporter is functional (Figure 3.2). 
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Figure 3.1 
Schematic diagram of Nanog Promoter Reporter 
The Nanog promoter of the vector is driven by the endogenous expression of 
Nanog to cause the expression of copGFP and confer Zeocin resistance. Nanog 
expression is key to pluripotency and this provides reprogramming progress 
tracking. T2A is self-cleaving peptide allow expression of copGFP and Zeocin 




Induction of D122_reNanog cells with pPyCAG-Nanog-IP 
After the transfection of D122_reNanog cells with pPyCAG-Nanog-IP using 
lipofectamine 2000. The expression of Nanog from pPyCAG-Nanog-IP drives 
the Nanog promoter in D122_reNanog and expresses green fluorscent protein. 
The green fluorescence was examined after 48 hours transfection. Expression of 
green fluorescence indicates the functionality of Nanog reporter. 
(a) Bright-field of D122_reNanog cells 
(b) Green fluorescence of D122—reNanog cells with pPyCAG-Nanog-IP vector 
transfected 
(c) Mock transfected D122_reNanog with empty vector pcDNA3 
(magnification: a,b,c, x25) 
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3.2 Nucleofection optimization for D122 
The transfection efficiency of D122 resulted from lipofectamine 2000 
was about 40%. It has been shown that the high expression of transcription 
factors is essential for nuclear reprogramming. Therefore, to improve the 
transfection efficiency, nucleofection was employed. 
Nucleofection is a transfection method to transfer nucleic acids into 
mammalian cells. The principle of nucleofection is based on the physical method 
of electroporation, with the uses of combination of electrical parameters, 
generated by nucleofector with cell-type specific reagents to introduce nucleic 
acid directly into cell nucleus and cytoplasm (Aluigi, et al., 2006; Leclere, et al., 
2005) 
To maximize the nucleofection efficiency, optimization was carried out 
to select the optimal condition for D122_reNanog. A pmaxGFP vector that 
expresses GFP which can be analyzed by flow cytometry was employed to 
monitor the nucleofection efficiency. Therefore, after nucleofection under 
different conditions, flow cytometry was used to assess the nucleofection 
efficiency (Table 3.1). 
Nucleofector solution V plus program T-30 was identified to be the 
optimal transfection condition for D122_reNanog and the efficiency achieved 
was 84%. This condition was used throughout the experiments. 
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Table 3.1 
Flow cytometry result from Nucleofection optimization 
Nucleofection optimization for D122_reNanog cell line, pmaxGFP was used for 
nucleofection. Flow cytometry was performed after 48 hours nucleofection. 
Nucleofection performed with solution V plus T-30 program yielded the highest 
green fluorescent signal and hence highest nucleofection efficiency. 
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3.3 Generation of D122-iPS 
3.3.1 Plasmid construct used in the study 
The conventional method to generate induced pluripotent stem cells is 
using retrovirus encoding Yamanaka transcription factors. Towards to the end of 
the reprogramming process, expression of the transcription factors wil l be 
silenced. However, it has been observed that during the subsequent 
differentiation process, reactivation of the transcription factors, notably the 
proto-oncogene, c-Myc, can occur. This poses a risk of tumorigenicity to cells 
which reduces the use of induced pluripotent stem cells. 
To minimize the risk of reactivation of the transcription factors when 
using the retroviral approach, I elected to employ the Cre/loxp excisable method 
to generate induced pluripotent stem cells. The loxp sites in the vectors allow the 
removal of transcription factors by transfecting Cre vectors after reprogramming. 
Moreover, in the conventional method, separate retrovirus containing 
individual transcription factors are used. Multiple integrations of transcription 
factors in the genome can occur. This increases the risk of insertion mutagenesis. 
The use of polycistronic vectors expressing multiple reprogramming factors from 
a single promoter using 2A peptides to bridge the factors allows minimal vector 
insertion. 2A peptides are identified as self-cleaving peptides allow expression of 
multiple, discrete proteins from a single ORF (open reading frame). 
To achieve the above conditions, I employed the vector 
pCAG2LMKOSimO from Kaji (Addgene 20866, Kaji, et al., 2009), which 
allows four transcription factors, Oct4, Sox2, Klf4 and c-Myc, from one transcript 
and contains loxp sites for Cre excision afterwards (Figure 3.3). 
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Schematic map of reprogramming vector pCAG2LMKOSimO (OSKM) 
The strong promoter CAG drives the expression of four transcription factors. The 
F2A, T2A and E2A are self-cleaving peptides allow expression of Oct4, Sox2, 
Kl f4 and c-Myc, from one transcript. Introduction of IRES allows the expression 
of mOrange protein in bicistronic mRNAs. The mOrange protein expression 
allows the tracking of plasmid. The loxp sites allow the excision from c-myc to 
mOrange by Cre-recombinase. The neomycin resistance gene allows the 
selection using antibiotics G418. The Pvul restriction site allows the 
linearalization of plasmid vector. 
(CAG: combination of the cytomegalovirus (CMV) early enhancer element and 
chicken beta-actin promoter) 
(IRES:Internal ribosome entry site) 
(Diagram is modified and redrawn from Kaji, et al, 2009) 
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3.3.2 Protocol ofD122-iPS generation 
Linearization of plasmid allows better stable transfection (Kreiss, et al., 
1999). Therefore, the OSKM plasmid was cut by the restriction enzyme Pvul, 
followed by gel electrophoresis to confirm the successful cutting and column 
purification before nucleofection. 
Fifty thousand D122—reNanog cells were nucleofected with 3|j.g Pvul 
linearized OSKM plasmid using nucleofector solution V using nucleofector I I 
machine with program T-30. Two days after nucleofection, the medium was 
switched from DMEM medium with 10% FCS to ES medium with LIF and 
2mg/ml G418 antibiotic. On day 9, G418 selected cells were plated on 
mitomycin treated SNL feeder cells in ESGRO medium. D122_reNanog colonies 
with green fluorescent signal were picked manually and subsequently cultured in 
1% gelatin-coated plate in ESGRO medium (Figure 3.4). 
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OSKM nucleofection Relate on SNL feeders Colony picking 
G418 selection 
I 
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 20 
I I I I 1 I I I i i i I I I I I I I I I i 
Medium L dm j esm 1 esgro "1 
Figure 3.4 
Schematic timeline of D122-iPS generation protocol 
D122_reNanog cells nucleofected with Pvul linearized OSKM plasmid using 
nucleofector solution V with program T-30. Two days after nucleofection, the 
medium was switched from D M E M medium with 10% FCS to ES medium with 
LIF and 2mg/ml G418 antibiotic. G418 selected cells were plated on mitomycin 
treated SNL feeder cells in ESGRO medium on day 9. D122一reNanog colonies 
with green fluorescent signal were picked manually at day 20 and subsequently 
cultured in 1% gelatin-coated plate in ESGRO medium. 
(DM, 10% FCS D M E M medium; ESM, ES medium; ESGRO, ESGRO serum-
free feeder-free medium.) 
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3.3.3 Reprogramming Efficiency of D122_reNanog cells 
The endogenous Nanog-GFP reporter in D122—reNanog was used to 
evaluate the reprogramming efficiency. Reprogramming efficiency was defined 
as the number of Nanog-positive colonies on SNL feeder cells on day 20. 
From three independent experiments, around 24-36 GFP positive colonies 
with induced pluripotent stem cells morphology were observed from 5*10^ 
D122—reNanog cells. Therefore, the reprogramming efficiency was 0.005%-
0.007% which is higher than the 0.001% in reprogramming mouse embryonic 
fibroblast (Brambrink, et al., 2008; Stadtfeld, et al., 2008). 
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3.4 Expression of pluripotency markers upon reprogramming 
Upon reprogramming, different pluripotency markers should be 
sequentially expressed. As the reprogramming potential for mouse lewis lung 
carcinoma was uncertain, therefore, I investigated whether pluripotency markers 
were expressed after nucleofection of OSKM plasmid. 
3.4.1 Alkaline Phosphatase Staining 
The undifferentiated state of ESC expresses alkaline phosphatase 
(Mitalipov Sh, et al., 1994; Saito, et al., 2004), and the expression of alkaline 
phosphatase was shown as the early sign of reprogramming (Brambrink, et al.’ 
2008，Stadtfeld, et al, 2008). 
In my study, after the nucleofection of D122_reNanog cells, I switched 
the culture medium were switched to ES medium at day 2 without addition of 
G418. Cells were collected from day 2 onwards and stained with NBT/BCIP for 
alkaline phosphatase. The alkaline phosphatase positive cells appeared on day 6 
(Figure 3.5). 
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Figure 3.5 
Alkaline phosphatase Staining using NBT/BCIP 
After nucleofection of D122—reNanog cells with OSKM plasmid, cells were 
collected at day 6. Collected cells were fixed with acetone and alkaline 
phosphatase staining was performed using NBT/BCIP. 
a) OSKM nucleofected Day 6 D122—reNanog cell, 
b) Control D122_reNanog cell 
Positive alkaline phosphatase cells stained blue where nuclei counterstained in 
red (Magnifi cation=x2 5). 
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3.4.2 Nanog-GFP expression 
Around seven days after introducing the Yamanaka transcription factors, 
small GFP-Nanog positive colonies emerged (Figure 3.6). This indicates the gain 
of pluripotency of D122—reNanog cells. However, as D122—reNanog cells are 
fast growing carcinoma, subsequent subculture was found to have diluting effect 
on GFP-positive cells. It has been shown that the expression of reprogramming 
factor for at least 8 days is necessary for reprogramming mouse embryonic 
fibroblast. Therefore, the G418 selection was used to select the nucleofected 




Morphology of Nanog-GFP-positive colonies 
Nanog-GFP-positive D122 colonies were first observed in day 7 
post-nucleofection. 
a, c) Phase contrast image of Nanog-positive colony, 
b, d) Fluorescence image of Nanog-positive colony. 
(Magnification: a,b, xlOO; c,d, x200) 
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3.4.3 Pluripotency gene expression upon reprogramming 
From the above results, I believed that the reprogramming process had 
taken place in D122—reNanog. To further study the process, pluripotency gene 
expressions were analyzed. After the nucleofection of OKSM into 
D122_reNanog cells, one 6-well of cells were collected at different time points. 
RNA was extracted and reverse transcription was carried out. Quantitative real-
time PGR (qRT-PCR) was carried out using SYBR Green Master Mix (Roche). 
From the qRT-PCR result (Figure 3.7), the endogenous expression of 
transcription factors Oct4, Sox2 and Klf4 were activated, along with the other 
pluripotency markers including Nanog, Rexl, Utfl, DppaS, Dppa4, Dppa5, 
Eactl, Eras, Esrrb, Klf2, Tell, and Dnmt3l. Coherent with the GFP-expression 







































 3  
^
^ 





 I  onli
fpc. 





















































































 a  
^
^ 


















I /  \  \ \  >〜〜
I
 \  <
/









































































 p  
§
.






























I /  <
/




 f  /  \  %  \  %
%
% 













































































































































































































































































































 ^  1
00
-
I  斷  T  * 
^  i
.
 鼸 咖 §  0  銘  •肪  0  .1  I  _國
：。•
 ,國 
_圓圓  I  20
-























































1  ^ 




 化  y  
细  re 
&  I  T E  m 
w  i.  hr  OT
 V
 鼸  
i  0  ^  fr t  • 哪§.  _  鄉“丨
—H





































































































































































































































































































































3.4.4 GFP positive D122_reNanog Colonies 
D122_reNanog cells were transfected with linearized OSKM plasmid, 
selected with 2mg/ml G418, replated on SNL on day 9，more GFP-expressed 
colonies were observed (Figure 3.8) and picked manually. The picked colonies 
were subcultured in gelatin-coated plate with ESGRO medium. 
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Figure 3.8 
Morphology of Nanog-GFP-D122 iPS 
1 a,b) Representative colonies ofNanog-GFP-D122 iPS on SNL feeder cells at 
day 20 (upon picking) at low magnification. Red circles represent the colonies 
picked. 
a) Phase contrast image, b) Fluorescence image 
2 a，b,c,d) Representative colonies ofNanog-GFP-D122 iPS on SNL feeder cells 
at day 20 (upon picking) at high magnification. 
a,c) Phase contrast image, b,d) Fluorescence image 
(Magnification: la, lb, x50; 2a, 2b, 2c, 2d, x400) 
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3.5 Characterization of the D122 iPS 
3.5.1 Morphology of D122-iPS-lC 
After picking, D122-iPS-lC was isolated. Homogenous GFP expression 
was observed (Figure 3.9) and sustained after 30 passages in ESGRO medium. 
The reprogrammed D122-iPS-lC should attain similar characteristics of 




Morphology of D122-iPS-lC 
1) Low magification a) Phase contrast image of D122-iPS-lC, 
b) Fluorescence image of D122-iPS-lC (Green channel), 
c) Fluorescence image of D122-iPS-lC (Red channel) 
2) High magification a)Phase contrast image of D122-iPS-lC, 
b) Fluorescence image of D122-iPS-lC (Green channel), 
c) Fluorescence image of D122-iPS-lC (Red channel) 
(Magnification: la,b,c, x25 ； 2a, b, c, x400) 
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3.5.2 Pluripotency gene expression 
The pluripotent gene expression of D122-iPS-lC was analyzed by 
quantitative real-time PCR (qRT-PCR). The D122-iPS-lC expressed various 
markers for undifferentiated ES cells, including Nanog, Utfl, c-Myc, Oct4, Sox2, 
DppaS, Dppa4 and DppaS in a comparable level in CCB mESC. And higher 
expression of Rexl and lower expression Klf4 was observed in D122-iPS-lC 
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Figure 3.10 
The expression levels of pluripotent genes quantified by qRT-PCR 
The expression levels of pluripotent genes quantified by qRT-PCR and plotted 
relative to CCB mESC expression. Expression of Tbp was used as an internal 
control. The data represent the relative mRNA expression levels with respect to 
the expression levels of each gene in CCB mESC. The data represent the mean 
values (n=3), error bar represents standard deviation. 
84 
3.5.3 Pluripotency markers SSEA-1 and Oct4 
As the mOrange expression disappeared in D122-iPS-lC (Figure 3.9c), in 
the following immunostaining，red channel was used for the antibody staining 
and the green channel represent the Nanog-GFP signal. 
The D122-iPS-lC clone expressed SSEA-1 (Figure 3.1 Id) and Oct4 
(Figure 3.12d) using immunostaining whereas little Oct4 expressions (Figure 
3.12f) and no expression in SSEA-1 in parental D122 (Figure S.l l f) . CCB mES 
were stained as positive control (Figure 3.11c, 3.12c). The overexposed red 
channel was used to demonstrate no red signal was observed before staining 
(Figure 3.1 lg,3.12g) 
To conclude, the above results demonstrate that D122-iPS-lC was similar 
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Figure 3.11 
ES cell marker, SSEA-1, staining on D122-iPS-lC 
D122-iPS-lC was fixed in 4% formalin, after blocking in 3% BSA in PBS. 
SSEA-1 (Stemgent) was used as primary antibody (1:100) and Alexa Fluor 568 
rabbit anti mouse IgG was used as secondary antibody(l:100). Both antibodies 
were stained in 3% BSA in PBS. 
Phase contrast image of a) D122-iPS-lC 
Fluorescence image of 
b) Parental D122 control, c) CCB rtiES control (inset showing the phase contrast 
image), d) D122-iPS-lC on SNL, 
e) GFP-signal from Nanog reporter of D122-iPS-lC, 
f) 2nd antibody only control of D122-iPS-lC (Negative control) 
g) Overexposure of D122-iPS-lC on red channel before staining 
(Magnification: a, b, c, d, f, g, x50) 
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Figure 3.12 
ES cell marker, Oct4, staining on D122-iPS-lC 
D122-iPS-lC was fixed in 4% formalin, after blocking in 3% BSA in PBS. Oct4 
(Stemgent) was used as primary antibody (1:100) and Alexa Fluor 568 goat anti-
rabbit IgG was used as secondary antibody (1:100). Both antibodies were stained 
in 3% BSA in PBS. 
Phase contrast image of a) D122-iPS-lC 
Fluorescence image of 
b) Parental D122 control, c) CCB mES control (inset showing the phase contrast 
image), d) D122-iPS-lC on SNL, 
e) GFP-signal from Nanog reporter of D122-iPS-lC, 
f) 2nd 肌tibody only control of D122-iPS-lC (Negative control) 
g) Overexposure of D122-iPS-lC on red channel before staining 
(Magni f icat ion: a, b，c, d, f , g，x50) 
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3.5.4 Bisulfite genomic sequencing 
Bisulfite genomic sequencing analysis evaluates the methylation status of 
cytosine guanine dinucleotides (CpGs) in the promoter regions of pluripotent 
associated Nanog (Figure 3.13). The Nanog promoter ofCCB mESC was highly 
unmethylated; whereas that of parental D122—reNanog was highly methylated. In 
D122-iPS-lC, partial methylation (27%) was observed indicating the 
pluripotency transcription program had occurred to at least some degree. 
Although the methylation status in D122-iPS-lC was not completely 
unmethylated (methylation status 27%), similar result was observed in blood 
cancer cell reprogramming (methylation status 15%) (Carette, et al., 2010). 
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Figure 3.13 
Bisulfite genomic sequencing of the promoter regions of Nanog 
Bisulfite genomic sequencing of the promoter regions of Nanog. Open and closed 
circles indicate unmethylated and methylated CpGs, respectively. Complete 
demethylation observed in CCB mES, and complete methylation observed in D122. 
Partial methylation of D122-iPS-lC reveals the reactivation of pluripotency 
transcription circuitry. 
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3.5.5 Differentiation potential of D122-iPS-lC 
After the reprogramming process, the induced pluripotent stem cells 
would demonstrate pluripotency. Therefore, to test the functionality ofiPS cells, 
differentiation potential was assessed. 
Here, I induced the differentiation of D122-iPS-lC using embryoid body 
formation (Mogi, et al., 2009, Itskovitz-Eldor, et al.’ 2000) and retinoic acid (RA) 
which can directly induce differentiation into the neural-like cells (Ying, et al” 
2003b). 
3.5.5.1 Embryoid Body formation by hanging drop 
After embryoid formation using hanging drop for 7 days in basal medium 
without LIF (Millipore), D122-iPS-lC embryoid bodies were put back on 
gelatin-coated plate in basal medium after 4 days. The clumps attached on the 
culture vessel and a variety of cells with different morphologies were observed 
(Figure 3.14)，resembling neuronal cells (indicated in black arrow), cobblestone-
like cells (indicated in yellow arrow), and epithelial cells (indicated in red arrow). 
90 
® * —-—…… ：：厂一-^  ：―…： ’…一一 - 一 —— • ， 
々 * m 
‘ , -；‘. . 麵 ‘ - 1 
. p v - 、 . • - , 
. .. 0 • 、 • - - � • 
- IT •， 
• 〜 A ‘ ： 
i? • ,3 .. 
... * - .» ？ 
© , ： € ‘ � i ‘ 
f 
‘ \ • , > ‘ 二丄？、 ’ j ：翁‘^ 
• . 也 、 〒 ， ， . - -广 、 -.:—— 
, -,：”4�.. 'V , V >了 . ‘ . • • . ‘ ’ 
CV , ，. ^ . - . 、• 
, . - ： 、 . • / • ‘ 厂 一 . ’ “ ‘ ？ 
：•• — • •‘ 
© D122 
」 . ” . 〜 . . ： > . 
。 \ - ：… . 
… 、 . . . 、 . ， 
. : . ' ‘ • « ... .: ‘ 
. ’ ^ ‘ -J- ‘“ 
- . - -.'4. “ 
- - — C. • 
. , • 
i . . • . ” 
- _ ； ._— •.‘.《<>...••_....—'._—.…_,^ , 
Figure 3.14 
Morphology of hanging drop induced differentiated cells from D122-iPS-lC 
cells 
After embryoid formation of D122-iPS-lC using hanging drop for 7 days in 
basal medium, then put back to gelatin-coated plate in basal medium after 1 day, 
a variety of cells with different morphologies were observed. 
(a, b, c，d) Phase contrast image of differentiated cells from D122-iPS-lC using 
hanging drop. The black arrows indicate the neural-like cells. The red arrows 
indicate the epithelial-like cells. The yellow arrows indicate the cobblestone-like 
cells. 
e) Phase contrast image parental D122 as control 
(Magnification: a, b, c, d, e, x25) 
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3.5.5.2 Retinoic acid induced differentiation 
It has been shown that the spontaneous neuronal differentiation of 
embryonic stem cells induced by all-trans-retinoic acid (RA) plays an important 
role in embryogenesis and early postnatal development (Gajovic, et al” 1997; 
Rohwedel, et al., 1999; Bibel, et al., 2004). 
The neural progenitors generated from ESC have been mostly defined by 
the expression of Pax6 (Walther and Gruss, 1991) and intermediate filament 
markers Nestin (Lendahl, et al., 1990). 
To induce the spontaneous neuronal differentiation in D122-iPS-lC, 
lO'^M retinoic acid in DMSO was added in the culture medium for four days. 
The neural-like cells appeared (Figure 3.15) and the proliferation of RA-added 
D122-iPS-lC was much slower when compared with parental D122 with RA 
addition. 
As the morphology of cells was not sufficient to identify the cell type, 
therefore, the neural-like cells were stained with Pax6 and Nestin. Pax6 and 
Nestin are markers for neural cells. Two hundred cells were counted using direct 
cell counting under microscope. About 80% of cells were staining positive with 
Nestin (Figure 3.16) and Pax6 (Figure 3.17) confirmed their neural lineage and 
showed that the D122-iPS-lC possess certain degree of differentiation potential. 
Similar results were obtained in ESC differentiation using the protocol (Bibel, et 
al., 2004). 
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Figure 3.15 
Morphology of D122-iPS-lC cells differentiated to neural lineage by retinoic 
acid 
D122-iPS-lC was differentiated using lO'^M retinoic acid in basal medium for 4 
days on gelatin-coated culture dish. 
(a, b, c, d) Phase contrast image of differentiated D122-iPS-lC. 
More homogenous neural-like cells observed, pointed by arrows. 
(e) Phase contrast image of parental D122 and 
(f) Phase contrast image of parental D122 under treatment of retinoic acid for 4 
days was used as control, D122-RA. 
(Magnification: a, b, c, d, e, x25; f，x50) 
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Figure 3.16 
Nestin immunostaining of Nestin on RA induced Neural-like D122-iPS-lC 
After direct differentiation of D122-iPS-lC using retinoic acid, differentiated 
cells were fixed in 4% formalin, after blocking in 3% BSA in PBS. Nestin 
antibody (Developmental Studies Hybridoma Bank) was used as primary 
antibody and Alexa Fluor 568 rabbit anti mouse IgG was used as secondary 
antibody(l:100). Both antibodies were stained in 3% BSA in PBS. 
a, c) Phase contrast image of of RA induced D122-iPS-lC, 
b,d) Fluorescence image of Nestin positive D122-iPS-lC, 
e) Phase contrast image of parental D122, 
f) Fluorescence image of parental D122, 
g) Fluorescence image of D122-iPS-lC using secondary antibody only (Negative 
control) 
(Magnification: a, b，e, f, g, x200; c, d, x400) 
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Figure 3.17 
Pax6 immunostaining of Nestin on RA induced Neural-like D122-iPS-lC 
After direct differentiation of D122-iPS-lC using retinoic acid, differentiated 
cells were fixed in 4% formalin, after blocking in 3% BSA in PBS. Pax6 
antibody (Developmental Studies Hybridoma Bank) was used as primary 
antibody and Alexa Fluor 568 rabbit anti mouse IgG was used as secondary 
antibody(l:100). Both antibodies were stained in 3% BSA in PBS. 
a, c) Phase contrast image of RA induced D122-iPS-lC, 
b，d) Fluorescence image of Pax6 positive D122-iPS-lC, 
e) Phase contrast image of parental D122, 
f) Fluorescence image of parental D122, 
g) Fluorescence image of D122-iPS-lC using secondary antibody only (Negative 
control) 
(Magnification: a,b，e,f,g，x200; c，d, x400) 
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Chapter IV Discussion 
4.1 General Discussion 
In this study, I sought to investigate a novel way of cancer 
immunotherapy as a proof of concept. The objective of the present work is 
generation of iPS cells from cancer cells. 
4.1.1 Cancer immunotherapy and dendritic cells 
Cancer is one of the leading causes of mortality and morbidity worldwide 
(Jemal, et al., 2010). The mainstream of cancer therapy includes surgery 
treatment, chemotherapy and radiotherapy. However, many tumors remain 
unresponsive to traditional therapy (Loebinger and Janes, 2010). Immunology is 
a major force in medicine (Steinman and Banchereau, 2007). A multitude of 
research was conducted in mice (Shankaran, et al., 2001, Dunn, et al., 2002) and 
human (Finn, 2008) demonstrating that the immune system is able to control 
cancer. 
The two main functions of immune system are to recognize antigens and 
to generate qualitatively distinct responses, including anti-tumor response. 
Dendritic cells (DCs) are the most potent antigen-presenting cells. It 
plays a critical role to induce, sustain and regulate responses of naive T cells 
(Steinman and Banchereau, 2007; Melief, 2008). There are two stages of DCs, 
immature and mature. Immature DCs are efficient in the uptake of antigens. 
Upon maturation, the antigen-loaded DCs are responsible for launching Ag-
specific immunity (Finkelman, et al., 1996), leading to T-cell proliferation and 
differentiation into cytotoxic T-cells causing cell death in antigen-specific 
manner (Lanzavecchia and Sallusto, 2001). DCs are also important for lauching 
humoral immunity by direct interaction with B cells (Jego, et al., 2005). 
The first therapeutic cancer vaccine Sipuleucel-T approved by U.S. FDA 
(Buonerba, et al, 2011) is an autologous, dendritic cell-based vaccine to treat 
castration-resistant prostate cancer patients. Ninety five percent of prostate 
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cancer cells express prostatic acid phophstase (PAP), a prostate specific antigen 
and prostate-specific membrane antigen. Dendritic cells of patient were collected 
and recombinant form of PAP with GM-CSF were loaded ex vivo. Then, prostate 
cancer patients immunized with three courses of Sipuleucel-T in a month. The 
clinical results of Sipuleucel-T show prolonged survival time (Buonerba, et al” 
2011). 
4.1.2 Dendritic vaccine and tumor antigen 
The general approach to cancer vaccines via DCs is based on the delivery 
of Ags directly to DC to induce the immunity. To elicit an effective immune 
response, suitable antigen and strategies to load antigens for dendritic cell 
recognition are crucial. 
Tumor cells have a wide range of genetic mutations and dysregulated 
gene expression. The mutated gene sequence results in production of mutated 
proteins, which are tumor-specific antigens, while dysregulated expression of 
otherwise normal protein leads to generation of tumor-associated antigens 
(TAAs). TAAs are employed in activating the anti-tumor immune response in 
immunotherapy. 
However, choosing suitable TAAs for cancer immunotherapy is not 
simple. The use of single tumor antigen often results in ineffective immune 
surveillance (Dunn, et al., 2002; Schreiber, et al., 2002; Ikeda, et al., 2002). The 
TAAS identified for particular cancer which are not presented by cell surface 
MHC limits their application in dendritic cell-mediated therapy as the cytotoxic 
T cell must recognize the MHC-presented antigen on the target cells to eliminate 
them (Ebstein, et al, 2004; Robinson, et al., 2000). Moreover, tumor is a 
heterogeneous population; targeting one antigen is not sufficient to generate 
complete tumor removal, as antigen loss variants wil l be selected (Smyth, et al., 
2006; Dunn, et a/., 2004). 
The use of whole tumor lysate for loading of DC is established to 
circumvent the need to characterize a specific tumor antigen for effective 
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immunization (Hegmans, etal, 2005; Fields, etal., 1998; Soleimani, et al, 
2009). However, several studies reported that tumor lysate can impair the 
function of DCs and result in limited immune response (Jackson, et al., 2008; 
Yang, et al, 2009; Hatfield, et al, 2008). Therefore, a more adequate method to 
manipulate dendritic cells so as to elicit sufficient immune response is demanded. 
The reduction of number of dendritic cells was observed in cancer 
patients (Lissoni, et al., 1999; Lissoni, et al, 2001; Hoffmann, et al, 2002). 
Although the effects of tumors in DC function remains poorly understood, 
reconstitution of dendritic cells induces potent CTL response against tumors 
(Frolkis, etal., 2003). 
4.1.3 Induced pluripotent stem cell technology and dendritic cells 
With the knowledge of induced pluripotent stem cell technology, it is 
now possible to convert differentiated cells into pluripotent cells by introduction 
of transcription factors including Oct4’ Sox2, Klf4 and c-Myc (Takahashi and 
Yamanaka, 2006). Differentiation of dendritic cells from embryonic stem cells 
(Fairchild, et al., 2000; Senju, et al., 2003) and induced pluripotent stem cells 
(Senju, et al., 2009) has been demonstrated. 
4.1.4 Tumor antigen presentation and dendritic cells 
A few reports demonstrated the reestablishment of pluripotency in 
malignant cancer cells using nuclear transplantation (Hochedlinger, et al., 2004) 
and induced pluripotent stem cell methodology (Miyoshi, et al., 2010; Nagai, et 
al., 2010). The reprogrammed cancer cells were able to differentiate into three 
germ layer teratoma and even an entirely tumor-ES-cell derived mice 
(Hochedlinger, et al, 2004) indicating a complete developmental ability of tumor 
derived stem cells. 
In previous study，dendritic cells derived from mouse embryonic stem 
cells transfected with human sequence plasmid vector had the ability to prime the 
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antigen-specific cytotoxic T cells, to elicit response to reject human antigen 
containing cells (Senju, et al” 2003). The oncogenic BCR-ABL protein 
continued to express in the induced pluripotent stem cells from blood maligant 
cells (Carette, et al., 2010). On the other hand, the expression of oncogene c-Myc 
decreased in D122-iPS-lC when compared with the parental D122 in my study, 
indicating the reduced expression of oncogene. 
Therefore, it is difficult to conclude whether the tumor antigens wil l 
remain expressed after reprogramming. However, I believe some of the tumor 
antigens, may not all, wil l continue to express in the induced pluripotent stem 
cells. And the tumor antigens express on the dendritic cells derived from induced 
pluripotent stem cells will elicit the anti-tumor antigen response. 
Although tumor antigens continue to express in dendritic cells, the short 
half-life of dendritic cells wil l soon be eliminated in body (Geissmann, 2007) and 
I believe the dendritic cells will not cause tumorigenicity in body except the anti-
tumor response. Therefore, the expression of tumor genes wil l not affect the 
future use of dendritic cells vaccine. 
4.1.5 D122 and cancer immunotherapy 
Mouse Lewis lung carcinoma D122 was chosen for this study because 
they demonstrate low immunogenicity and are highly metastatic. Besides, D122 
is frequently used in dendritic cell therapy experiments (Porgador, et al.’ 1993; 
Carmon, et aL, 2000; Goldman, et al., 2000; Kawarada, et al., 2001; Pan, et al., 
2005; Ramirez, et al., 2006; Xia, et al., 2006; Zhu, et al” 2006; Garrido, et al, 
2007; Labrada, et al., 2010). D122 is able to form fast growing tumor in 
allogenic and syngenic mice. Thus, the low immunogenicity of D122 allows the 
least ambiguousity when assaying the immunogenicity of the dendritic cells 
differentiated from D122 through reprogramming. Therefore, D122 cell line is a 
good model to use in this study. 
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4.1.6 Method to introduce transcription factors for reprogramming 
Currently, many different methods have been employed to introduce the 
reprogramming transcription factors, including retroviral (Takahashi and 
Yamanaka, 2006) and excisable lentivirus transduction (Somers, et al, 2010)， 
and multiple transient plasmid transfections (Si-Tayeb, et al, 2010b; Yusa, et al., 
2009; Hu, etal,20\\). ‘ 
The generation of induced pluripotent stem cells using retrovirus causes 
stable integration of retroviral DNA in the host genome, leading to insertion 
mutagenesis. Moreover, reactivation oftransgenes is often observed in 
differentiated cells from induced pluripotent stem cells and induce tumor 
formation in iPS-cell-derived chimeric mice (Aoi, et al., 2008). Furthermore, the 
expression of transcription factors reduces the differentiation potential of induced 
pluripotent stem cells (Kaji, et al., 2009). 
To minimize the potential hazard created by virus-based method, the 
stable plasmid transfection approach was used in this study. This approach 
introduces the transcription factors in a single polycistronic vector with loxp-Cre 
site for subsequent excision after reprogramming (Kaji, et al., 2009). 
After the plasmid transfection, the stable expression of transcription 
factors enables the reprogramming to take place (Brambrink, et al., 2008). The 
loxp sites in plasmid allow the removal of transcription factors after 
reprogramming. The removal of transcription factors prevent the expression of 
proto-oncogene c-Myc after reprogramming which will reduce the risk of 
tumorigenicity (Okita, et al., 2007). 
Inevitably, a part of plasmid vector of the Cre-excised cells will remain. 
The cells include a strong CAG promoter which may cause the abnormal 
expression of neighbouring genes. However, only one insertion was usually 
resulted in plasmid-generated induced pluripotent stem cells (Kaji, et aL, 2009) 
whereas multiple ones were found when virus was used (Takahashi and 
Yamanaka, 2006). The plasmid-based approach reduce the risk of insertion 
mutagenesis and minimize undesired gene expression i f cells were selected 
carefully (Aoi, et al, 2008). 
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4.1.7 Kinetics of reprogramming 
There are only a few reports on reprogramming cancer cells to induced 
pluripotent stem cells (Miyoshi, et al” 2010; Nagai, et al, 2010). The 
reprogramming process and the pluripotency state of the reprogrammed D122 
require careful investigation. I elected to use Nanog-GFP reporter to generate 
D122_reNanog cell line as Nanog is completely inactivated in somatic cells and 
a crucial marker for complete developmental potential for induced pluripotent 
stem cells (Maherali, et al, 2007; Okita, et al, 2007;Wemig, et al., 2007). With 
the use of D122_reNanog, the reprogramming kinetics could be followed. 
The established reprogramming protocol was able to generate the alkaline 
phosphatase positive cells and Nanog-GFP positive D122 cells in day 6 and day 
8 respectively after the introduction of transcription factors by transfection. 
Consistently, qRT-PCR studies show that the endogenous expressions of 
transcription factors Oct4, Sox2 and Klf4 were started and increased from day 6 
after transfection, along with other pluripotency markers including Nanog, Rexl, 
Utfl, DppaS, Dppa4, Dppa5, Ecatl, Eras, Esrrb, Klf2, Tell and Dnmt3l, 
indicating that the reprogramming process is initiated after the transcription 
factors are introduced. 
The selection of pluripotency genes is based on their importance in 
maintenance of pluripotency (Kaji, et al” 2009). Nanog, Rexl and Utfl are 
highly enriched in ESC (Mitsui, et al., 2003). The expression of Utfl (Okuda, et 
al., 1998) and Rexl (Rogers, et al, 1991) are identified as ES cell specific 
markers. The overexpression of Nanog (Chambers, et al., 2003, Mitsui, et al., 
2003) and Esrrb is able to maintain self-renewal and pluripotency (Zhang, et al., 
2008). Eras (Takahashi, et al” 2003), DppaS and Dppa4 (Ramalho-Santos, et al., 
2002) expresses specifically in mESC. DppaS is exclusively associated with 
pluripotency (Kim, et al., 2005). Tell is a regulator of mESC pluripotency 
(Pritsker, et aL, 2006). Klf2 is able to substitute Klf4 to reprogram mouse 
embryonic fibroblast (Nakagawa, et al, 2008). Dnmt3l is essential for the 
methylation patterns in development of early embryo (Hata, et al., 2002). 
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Dppa4 and DnmtSl genes were not initiated after 15 days since 
nucleofection. One possible reason is that the DnmtSl is responsible for 
methylation patterns and this occurs in latter stage of reprogramming, beyond 15 
days. For Dppa4, the molecular function is not yet discovered. However, the 
expression of Dppa4 comparable with CCB mES cells in D122-iPS-lC 
represents that Dppa4 might be slow response and activate in latter time. Similar 
result was observed in induced pluripotent stem cells generated by plasmid-based 
method (Kaji, et al., 2009). 
4.1.8 Culture condition for reprogramming D122 reNanog 
In the beginning of study, ES medium without feeder cells was used in 
the whole process to generate induced pluripotent stem cells from 
D122—reNanog cells. However, the Nanog-GFP signal in nucleofected cells 
disappeared in day 27, a week after picking. 
This result indicated the reprogrammed D122—reNanog cells lost their 
pluripotency state in this culture condition. Therefore, I used mouse embryonic 
fibroblast as feeder cells to support the reprogramming process and better 
maintain their pluripotency state after reprogramming. In accordance with Okita 
research on optimizing induced pluripotent stem cells generation protocol 
(Okada, et al., 2010), SNL feeder layer generates better quality of induced 
pluripotent stem cells and it is easiler to handle. Therefore, I used SNL feeder 
cell line since then and stated in this thesis. 
However, the use of feeder cell line to culture induced pluripotent stem 
cell is time consuming and labour-intensive. Thus, the serum-free culture 
condition enhances the reprogramming process (Okada, et al, 2010; Chen, et al., 
2010). ESGRO Complete PLUS Clonal Grade Medium (Millipore) which is 
serum-free and support the growth of mESC in feeder-free condition 
supplemented with GSK3B inhibitor, BMP4 and LIF in serum-free culture 
condition have been shown to enhance the reprogramming process, possibly by 
inhibition of differentiation (Theunissen, et al, 2011). 
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Therefore, the ES medium switched to ESGRO medium at day 9 with the 
support of SNL feeder cells. SNL feeder cells were used to support the 
reprogramming process till 20 days after nucleofection. After picking the 
colonies, ESGRO medium without feeder layer was used to culture the 
established clones. This reduces the feeder cells contamination and maintains the 
pluripotency. ESGRO medium was used to culture CCB mESC and D122-iPS-
IC in this study. 
4.1.9 Reprogramming efficiency 
To evaulate the reprogramming efficiency, Nanog-GFP colonies were 
counted at day 20 on SNL feeder cells and it was 0.005-0.007%. It is a bit higher 
than the reprogramming efficiency observed in mouse embryonic fibroblast 
(-0.001%). This may due to the high endogenous level of c-Myc which has been 
shown c-Myc enhances the reprogramming process by the opening and 
maintenance of active chromatin (Knoepfler, et al., 2006). 
4.1.10 Establishment of D122-iPS-lC 
In this work, I have studied the early reprogramming process and 
achieved the generation of induced pluripotent stem cell D122-iPS-lC from 
D122. 
Using Nanog-GFP expression and morphology to identify the 
reprogrammed D122_reNanog, D122-iPS-lC cell line was established. It showed 
initial homogenous Nanog-GFP expression and the GFP signal sustained for over 
30 passages indicating a relative stable pluripotent condition. The pluripotency of 
D122-iPS-lC has showed similar characteristics of ESC, including surface 
marker SSEA-1, Nanog and Oct4 expressions and similar pluripotent gene 
expression levels with CCB mES (Okita, et al, 2007; Wemig, et al., 2008; 
Wernig, et al., 2007; Brambrink, et al.’ 2008; Stadtfeld, et al., 2008). 
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Moreover, the down-regulation of oncogene c-Myc to normal level was 
observed in the D122-iPS-lC showing that the tumor state of D122-iPS-lC was 
reversed. In other studies, the original c-Myc level in normal cells and primary 
cells is low when compared with expression in stem cells. After reprogramming, 
c-Myc level is up-regulated to the same level as stem cells (Takahashi & 
Yamanaka 2006; Kaji, et al., 2009). However, as D122 is a tumor cell line, c-
Myc expression is much higher. Moreover, in the few reports of using tumor cells 
for reprogramming, little data addresses this matter. Therefore, it is difficult to 
explain the down-regulation of c-Myc level in D122-iPS-lC after reprogramming. 
Down regulation of oncogene c-Myc may be an indication of reversing the 
tumor-phenotype of D122 after reprogramming. However, it is difficult to 
conclude and the tumor antigens expressions of D122-iPS-lC need to be 
confirmed in the latter experiments. 
4.1.11 Differentiation of D122-iPS-lC 
Differentiation process of ESC is induced when MEF feeder layer is 
withdrawn or LIF removed from culture medium (Glover, et al.，2006, Palmqvist, 
et al., 2005). Two basic methods have been developed to promote controlled 
differentiation. First, formation of three-dimensional aggregates known as 
embryoid bodies (EBs) by hanging drop or growing on ultra-low attachment 
plate: the embryoid bodies allows the differentiation into three germ layers 
(Mogi, et al., 2009) and almost all cell types (Itskovitz-Eldor, et al, 2000). 
Second, to induce ESCs to differentiate into particular lineage using 
specific inducers (Yasunaga, et al., 2005; Kubo, et al., 2004). For example, the 
trans-retinoic acid (RA) induces a pure population of neural precursor cells on 
monolayer culture system (Ying, et al., 2003b). Retinoic acid is an established 
signaling molecule involved in neuronal patterning, neural differentiation and 
axon outgrowth (Jones-Villeneuve, etal, 1983; Maden，2007; Lu, et al., 2009). 
The neural progenitors generated from ESC have been mostly defined by 
Pax6 (Walther and Gruss, 1991) and intermediate filament markers Nestin 
(Lendahl, et al., 1990). Pax6 is a transcription factor promotes neurogenic cell 
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fates during development (Stoykova and Gruss, 1994; Gotz, et al., 1998; Heins, 
et al., 2002) and also critical for neuronal differentiation (Sansom, et al., 2009). 
Nestin expresses mostly in nerved cells (Gilyarov，2008) and is regarded as a 
marker of neural progenitor cells (Fukuda, et al.’ 2003; Galvan and Bredesen, 
2007). 
Although I have not yet produced Cre-excised D122-iPS-lC, certain 
differentiation potential has been shown. Using hanging-drop embryoid body 
formation cells with different morphology were observed, including neuronal 
cells cobblestone-like cells and epithelial cells (Egusa, et al., 2010). 
Using retinoic acid to induce differentiation, D122-iPS-lC cells turned 
into neuronal-like cells, they were further characterized using Nestin and Pax6 
staining, neuronal specific markers, showing that 80% of D122-iPS-lC was 
differentiated into neuronal lineage. Similar result was obtained when ESCs were 
under retinoic acid induction (Ying, et al., 2003b). 
This result demonstrates that the non-excised D122-iPS-lC exhibits 
certain degree of differentiation potential. Although I have not yet differentiated 
D122-iPS-lC into dendritic cells in this study, the ability of D122-iPS-lC 
differentiate into different type of cells and neural cells upon retinoic acid 
induction showing the possibility to differentiate D122-iPS-lC into dendritic 
cells, hence used in the cancer immunotherapy. 
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4.2 Future Work 
In this study, I have established un-excised D122-iPS-lC cell line. It is a 
beginning of the ultimate objective to generate a novel dendritic cell cancer 
therapy. With this established cell line, the next step is to generate transgene-free 
D122-iPS-lC using Cre-recombinase as it has been shown that transcription 
factors-excised induced pluripotent stem cells have greater differentiation 
potential (Kaji, et al” 2009). Also, injecting the Cre-transfected cells into 
NOD/SCID mice to form teratoma consisting three germ layers is a more 
stringent test of pluripotency (Hentze, et al., 2009). This is then followed by the 
differentiating the transgene-free D122-iPS-lC into dendritic cells using 0P9 
feeder layer, with the stimulation ofGM-CSF and IL-4 (Senju, et al, 2009). 
The dendritic cells derived will be used to test the protective effectiveness 
against D122 challenge. Utimately, it is aimed to demostrate whether these 
dendritic cells could trigger rejection of the established tumor when injected into 
D122-tumor-bearing-mice. The result wil l show the efficacy of this approach on 
cancer immunotherapy. 
To test the proper anti-tumor response induced by dendritic cells, a series 
of experiments wil l be taken place. C57/BL6 mouse would be first injected with 
D122 cell to induce localized tumor and metastatic tumor. The D122-iPS-lC 
generated dendritic cells would be injected into mouse intraperitoneally with 7-
day interval between injections (Senju, et al., 2009). Size of tumor and status of 
tumor mouse would be recorded in time series manner, to see whether localized 




The induced pluripotent stem cell line D122-iPS-lC has generated using 
a single non-viral plasmid vector. The generated cell line expressed similar ESC 
phenotypes including surface markers; gene expressions and ability to 
differentiate were observed. This provides a model to further differentiate into 
dendritic cells to study the therapeutic potential in cancer immunotherapy. 
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Appendix 




lOmM PIPES (pH 6.7) 
ES medium (500ml) 
Component Volume Final conc. 
KnockOUT DMEM 400ml 
ES cell FBS (meets USDA import 100 20% 
requirements, Mexico origin) 
lOOX L-glutamine 5ml 2mM 
lOOX Penicillin and Streptomycin 5ml IX 
lOOX non-essential amino acids 5ml O.lmM 
1OOX EmbryoMax ES cell Qualified 2- 5ml 10'^ ^M 
Mercapethanol 
1 OOX EmbryoMax ES cell Qualified 5ml IX 
Nucleosides 
10'U/ml ESGRO LIF 500ul 1 OOOU/ml 
IX ES freezing medium (10ml) 
Component Volume Final conc. 
DMEM medium 5ml 50% 
Heat inactivated ES-FBS 4ml 40% 
DMSO 1ml 10% 
SNL medium 
Component Volume Final conc. 
DMEM medium 450ml 
Heat inactivated FBS 50ml 10% 
Penicillin and Streptomycin 5ml 1% 
Freezing medium 
Component Volume Final conc. 
DMEM medium 7ml 70% 
Heat inactivated FBS 2ml 20% 
DMSO 1ml 10% 
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